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POPULAR SCIENCE SUMMARY OF THE THESIS 
What is known and what remains to be answered?  
Esophageal cancer is a malignant disease which carries a poor prognosis. Among patients 
who are diagnosed with esophageal cancer, less than 20% survive more than 5 years after 
diagnosis. Surgery (i.e., esophagectomy) is the mainstay of curative treatment, which is 
applicable to around 25% of patients with esophageal cancer. However, esophageal cancer 
surgery is a major procedure, and even among patients undergoing the curatively intended 
surgery, less than 50% of them survive more than 5 years. Furthermore, after surgery, 
patients usually suffer from impaired health related quality of life (HRQL) such as pain, 
fatigue, eating difficulty, psychological distress, and decreased functioning.  
Improving survival and HRQL after esophageal cancer surgery are important and 
challenging. To address this, firstly we need to understand why the prognosis varies among 
individuals. Previous research has found that some sociodemographic and clinical factors 
could predict survival and HRQL. For example, patients with advanced tumor are more likely 
to have shorter survival and worse HRQL. However, it has also been found that even among 
patients with similar sociodemographic and clinical characteristics, the prognosis still varies. 
Thus, there must be other factors explaining the residual variation.   
The Greek philosopher Heraclitus says that “a man's character is his fate”. Also, more and 
more psychological studies have found that personality traits may affect our behavior and 
thus determine our fate to some extent. So, could personality traits explain the residual 
variation in the prognosis after esophageal cancer surgery? In addition, many people tend to 
believe that being optimistic might enhance patients’ survival chances and improve their 
HRQL, and caregivers sometimes encourage patients to try to be optimistic about their future 
even if they are facing a potentially fatal esophageal cancer. Such beliefs and actions based 
on folk wisdom carry a hope to improve survival and HRQL via being optimistic. However, 
whether optimism truly relates to the prognosis after esophageal cancer surgery remains 
unknown. 
What has this thesis studied?  
Dispositional optimism is a personality trait, which is the general expectancy that good rather 
than bad things would happen in the future. In this thesis, we used Swedish nationwide 
population-based data to examine whether higher dispositional optimism was associated with 
better prognosis after esophageal cancer surgery. At 1 year after surgery for esophageal 
cancer, we measured patients' dispositional optimism level using a self-reported scale called 
Life Orientation Test-Revised. At 1, 1.5, and 2 years after esophagectomy, we measured 
patients’ psychological status and HRQL using several self-reported scales such as the 
Hospital Anxiety and Depression Scale, the European Organization for Research and 
Treatment of Cancer Quality of Life Core questionnaire, and Gastro-Esophageal Specific 
questionnaire. We also obtained patients’ mortality information from the Swedish Total 
Population Register.  
What has this thesis found? 
We found that more optimistic patients were less likely to report psychological distress 
(anxiety and/or depression) and were more likely to report better HRQL such as less pain, 
less eating difficulty, and better social function (Study I and II). Moreover, we also found 
that before the COVID-19 pandemic, among patients with early and intermediate tumor 
stages (pathological tumor stage Tis-II), more optimistic patients were more likely to survive 
longer (Study IV). However, this significant association was not observed among patients 
with advanced tumor stage (pathological tumor stage III-IV) and/or when the follow-up was 
during the COVID-19 pandemic (Study IV). In addition, we also found that psychological 
distress and HRQL might be causally associated (Study III). However, we cannot determine 
the causal direction. In other words, it could be that psychological distress caused worse 
HRQL, but it could also be the other way around (Study III).  
What is the implication of the thesis results?  
The results of this thesis support the intuition that more optimistic people have a better 
prognosis after surgery for esophageal cancer. Measuring dispositional optimism may help us 
identify vulnerable patients with potentially worse prognosis, and thus provide timely and 
tailored interventions to help them. In addition, given that psychological distress and worse 
HRQL might cause each other, in order to avoid or break the vicious circle, it is important to 








Dispositional optimism is a personality trait that represents generally favorable expectations 
about the future. The main aim of this thesis was to examine whether higher dispositional 
optimism was related to better subjectively reported outcomes and better objectively 
measured outcomes. We used a self-reported scale, Life Orientation Test-Revised (LOT-R), 
to measure dispositional optimism in this thesis, with a higher LOT-R sum score representing 
higher dispositional optimism. Data for the four studies included in this thesis were from a 
prospective, Swedish nationwide, and population-based cohort entitled “Oesophageal Surgery 
on Cancer patients - Adaptation and Recovery (OSCAR)”. 
Study I and II included 192 patients who underwent surgery for esophageal cancer during 
January 1, 2013 and February 28, 2018 in Sweden. Patients self-reported their dispositional 
optimism level at 1 year after surgery. At 1, 1.5, and 2 years after esophagectomy, patients 
repeatedly self-reported their psychological status and health related quality of life (HRQL). 
Latent growth curve model and linear mixed effects model were used in these two studies. 
We found that higher dispositional optimism predicted a lower risk of reporting clinically 
significant psychological distress (anxiety and/or depression) in study I. The odds ratio of 
reporting clinically significant psychological distress was 0.56 (95% confidence interval 0.40 
to 0.79) for one unit increase in the LOT-R sum score. In Study II, we categorized patients 
into four subgroups with very high, moderately high, moderately low, and very low 
dispositional optimism based on the quartile of the LOT-R sum score. We found that patients 
with very high and moderately high dispositional optimism reported better HRQL in several 
aspects compared to patients with lower dispositional optimism.  
Study III included 180 patients who underwent surgery for esophageal cancer during January 
1, 2013 and February 28, 2018 in Sweden. Patients self-reported their psychological status 
and HRQL repeatedly at 1, 1.5, and 2 years after esophagectomy. We used fixed effects 
regression model with adjustment for all time-invariant covariates and observed time-varying 
confounders, and found that psychological distress was associated with worse HRQL in 
several aspects.  
Study IV included 335 patients who underwent surgery for esophageal cancer between 
January 1, 2013 and December 31, 2019 in Sweden. Patients were followed up until the date 
of death or until December 31, 2020, whichever occurred first. Cox proportional hazards 
regression was used. We found that among patients with early and intermediate pathological 
tumor stages (Tis-II) and with follow-up period before the COVID-19 pandemic, the adjusted 
hazard ratio for all-cause mortality was 0.89 (95% confidence interval 0.81 to 0.98) for one 
unit increase in the LOT-R sum score. However, this association was not statistically 
significant for patients with tumor pathologically staged III-IV (hazard ratio 0.99, 95% 
confidence interval 0.92 to 1.07) and/or during the COVID-19 pandemic (hazard ratio 1.08, 
95% confidence interval 0.94 to 1.25).    
In conclusion, before the COVID-19 pandemic, higher dispositional optimism was associated 
with less self-reported clinically significant psychological distress and better HRQL; 
moreover, among patients with early and intermediate pathological tumor stages, higher 
dispositional optimism also predicted better overall survival. Measuring dispositional 
optimism may help identify vulnerable patients with potentially worse prognosis after surgery 
for esophageal cancer, thus contributing to the development of more tailored and timely 
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Esophageal cancer is an aggressive disease with a poor prognosis due to its late-onset 
symptoms. Surgery (esophagectomy) is the mainstay of curatively intended treatment, but the 
5-year survival rate after surgery for esophageal cancer is still less than 50%. Moreover, 
getting a cancer diagnosis and undergoing esophagectomy are traumatic stressors to patients, 
which entail high prevalence of psychological distress and substantially impaired health 
related quality of life (HRQL). Patients’ sociodemographic and clinical characteristics cannot 
fully explain the variations in the prognosis after esophageal cancer surgery. Whether 
psychological factors such as personality traits could explain the rest variations remains 
unknown. Dispositional optimism is a personality trait, which represents generally favorable 
expectations for the future. Previous studies have found that it is associated with both 
subjective wellbeing and objective physical health. However, whether dispositional optimism 
could predict prognosis after esophageal cancer surgery needs to be further explored. 
This thesis aimed to investigate the potential roles of psychological factors especially 




2 LITERATURE REVIEW 
2.1 ESOPHAGEAL CANCER 
2.1.1  Overview  
Esophageal cancer is a malignant neoplasm with an overall 5-year survival rate of less than 
20%,1,2 The poor prognosis is partly due to the late presentation of symptoms. Clinical 
symptoms of esophageal cancer include dysphagia, odynophagia, involuntary and progressive 
weight loss, chest pain, and fatigue, which are sometimes accompanied by hoarseness, cough, 
vomiting, and melaena.3,4 Owing to the muscular and expansible nature of the esophagus, 
early-stage cancers are rarely symptomatic. Patients usually present with symptoms when the 
cancer has progressed to a relatively advanced stage,3,4 which implies a poor prognosis.  
Esophageal cancer can be categorized into two main histological subtypes: esophageal 
squamous cell carcinoma and esophageal adenocarcinoma. Although the prognoses for these 
two subtypes of esophageal cancer are similar, their epidemiological and pathophysiological 
characteristics are divergent. In 2012, esophageal squamous cell carcinoma accounted for 
around 87% of the esophageal cancer cases worldwide, while esophageal adenocarcinoma 
accounted for around 12% of the cases.5 In addition, most cases of esophageal squamous cell 
carcinoma occur in South-Eastern and Central Asia, Eastern Africa, and Southern America, 
while esophageal adenocarcinoma is mainly prevalent in Northern America, Northern and 
Western Europe, and Oceania.5 This discrepancy in geographical distribution is partly related 
to different risk factors for these two subtypes of esophageal cancer. For esophageal 
squamous cell carcinoma, risk factors include tobacco smoking, alcohol overconsumption, 
low socioeconomic status, thermal injury, micronutrient deficiencies, high intake of red meat, 
low intake of vegetables and fruit, and genetic factors.3,4,6-11 Some studies have found that 
human papillomavirus infection might also play a role in the development of esophageal 
squamous cell carcinoma.12 For esophageal adenocarcinoma, the risk factors include chronic 
gastro-esophageal reflux, Barrett’s esophagus, central obesity, tobacco smoking, male sex, 
high intake of red meat, low intake of vegetables and fruit, and genetic factors.3,4,13-18 
Esophageal squamous cell carcinoma and adenocarcinoma also differ in tumor location, 
which is partly because of the anatomical and histological features of the esophagus as well 
as the different risk factors for these two subtypes of cancer. In brief, esophageal squamous 
cell carcinoma occurs more commonly in the upper and middle thirds of the esophagus, while 
esophageal adenocarcinoma is more common to be found in the distal esophagus.4        
The health burden from esophageal cancer is heavy. Esophageal cancer ranks as the 7th most 
commonly diagnosed cancer worldwide, and is the 6th leading cancer-specific cause of death 
globally.19 Owing to the improvement of living standard and changes in the tobacco smoking, 
the global incidence rate for esophageal squamous cell carcinoma has decreased substantially 
in recent years, especially among men.20,21 However, the incidence rate for adenocarcinoma 
in western countries has increased, possibly due to the increasing occurrences of reflux 
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disease, Barrett’s esophagus, and obesity, which makes adenocarcinoma become the 
dominant subtype of esophageal cancer in western populations.21,22      
2.1.2 Treatment 
Options of treatment for esophageal cancer include endoscopic management, esophagectomy 
with or without neoadjuvant chemoradiotherapy or chemotherapy, definitive chemoradiation, 
and palliative treatment.4 The choice of treatment depends on the characteristics of both the 
patient (e.g., age, comorbidity, and nutritional status) and the tumor, mainly the tumor-node-
metastasis (TNM) stage.4 T represents the size of the primary tumor and the depth of the 
invasion. N describes invaded regional lymph nodes. M stands for the occurrence of distant 
metastasis outside the field of traditional resection.4 The TNM classification is based on the 
guideline from the American Joint Council on Cancer (8th version).23 Esophagus has four 
layers, which from inner to outer are: mucosa, submucosa, muscularis propria, and adventitia. 
Esophageal neoplasm grows from the inner surface to the outside. T1a means that tumor 
invades mucosa (the first layer) while T1b means that tumor invades submucosa (the second 
layer).23 T2 indicates that tumor invades muscularis propria (the third layer),23 and T3 means 
that tumor invades adventitia (the fourth layer).23 T4 suggests that tumor invades adjacent 
structures.23 N0 refers to no invaded regional lymph node, while N1, N2, and N3 represent 
that 1-2, 3-6, and ≥7 regional lymph nodes have been involved, respectively.23 M0 indicates 
no distant metastasis while M1 suggests at least one distant metastasis.23 For esophageal 
cancer with very early stage such as T1aN0M0, endoscopic management like endoscopic 
mucosa resection or endoscopic submucosal dissection could be performed.4 In addition, for 
patients with tumor staged T1bN0M0 or who are unsuitable for surgery due to poor general 
health status, endoscopic submucosal dissection could also be attempted.4 For tumor staged 
T1b or T2 with N0M0, esophagectomy alone could be considered.3,4 However, for locally 
advanced tumor (T3-4 or N1-3, M0), esophagectomy together with chemoradiotherapy or 
chemotherapy are required.3,4 Definitive chemoradiation is mainly recommended for 
esophageal squamous cell carcinoma, but it could also be considered for patients with 
esophageal adenocarcinoma who are ineligible for surgery.3,4 Palliative treatment is mainly 
performed for patients with unresectable tumor at diagnosis or with cancer recurrence.3,4   
Surgery (esophagectomy) with or without neoadjuvant therapy is the primarily curative way 
to treat esophageal cancer. Only around 25% of the patients with esophageal cancer are 
eligible for surgical resection.3,4 The operation is extensive and followed by a high 30-day 
postoperative mortality rate, a high incidence of postoperative complications, and severely 
compromised health related quality of life (HRQL).1,24-27 Moreover, the 5-year postoperative 
survival rate is still less than 50%.1,24-27 There are three main surgical approaches: open 
esophagectomy (transthoracic or transhiatal), hybrid minimally invasive esophagectomy 
(laparotomy plus thoracoscopy or laparoscopy plus thoracotomy), and total minimally 
invasive esophagectomy (laparoscopy and/or thoracoscopy).3,4 The choice of the surgical 
approach largely depends on the hospital tradition or the preference of surgeons.28 One meta-
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analysis has demonstrated that long-term survival after minimally invasive esophagectomy is 
comparable with or may even be better than the survival after open esophagectomy.29 
Randomized controlled trials have also found that compared with open esophageal resection, 
minimally invasive esophagectomy has comparable 3-year survival, decreased incidence of 
pulmonary complications, shorter hospital stay, and better short-term HRQL.30-33 Moreover, a 
meta-analysis has shown that compared with patients receiving open esophagectomy, patients 
receiving minimally invasive esophagectomy report better physical function and global 
quality of life as well as less fatigue and pain until 3 months after surgery, but the difference 
does not remain at 6 and 12 months postoperatively.34  
2.2 CANCER SURVIVORSHIP  
Cancer survivors refer to patients diagnosed with cancer. Their family members, friends, and 
caregivers are cancer co-survivors.35,36 The experience of cancer survivors and co-survivors 
from cancer diagnosis onwards is cancer survivorship,35-37 which is defined as “living with, 
through, and beyond cancer”.36 Accordingly, cancer survivorship contains three phases36,37: 
(1) Acute survivorship (living with cancer): it is a treatment phase starting from cancer 
diagnosis and lasting until the completion of the initial treatment.36,37 (2) Extended 
survivorship (living through cancer): it is a watchful waiting phase after treatment, during 
which patients visit their oncologists regularly and watch out for cancer recurrence.36,37 (3) 
Permanent survivorship (living beyond cancer): it is a “cure” phase, where the risk of cancer 
recurrence is low and patients gradually return to the new “normal” life.36,37 Improving 
HRQL and psychological well-being are important goals of cancer survivorship.35,37  
 
Figure 1. “Cancer Survivor Ship”: a journey from cancer diagnosis to the end of the lifespan.   
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2.2.1 Health Related Quality of Life (HRQL) 
2.2.1.1 Overview 
The meaning of quality of life varies among different populations and different 
circumstances, and there is no universal definition regarding quality of life.38 In medical field, 
HRQL is frequently used.38 It is universally agreed that HRQL is a multidimensional 
construct describing subjective health status, which usually includes four dimensions: 
physical function, emotional function, social function, and symptoms.38,39 
When measuring HRQL, “ask the patient” is essential.38 Healthcare professionals and 
patients’ relatives usually provide biased evaluations of patients’ general quality of life and 
symptom experiences, so the core to assess HRQL is asking patients to report it by 
themselves.38 Thus, HRQL is a form of patient-reported outcomes reflecting patients’ 
opinions regarding the influences of disease and/or treatment on their daily lives.38,39 
A sizable body of instruments have been developed to measure HRQL. These measures could 
be classified into three groups: generic instruments, disease-specific instruments, and aspect-
specific instruments.38,39 Generic instruments can be used irrespective of the respondent’s 
health condition. Medical Outcome Study 36-Item Short Form (SF-36) and EuroQoL (EQ-
5D) are representatives of generic instruments.38 Disease-specific instruments focus more on 
the issues of a particular disease.38 For example, European Organization for Research and 
Treatment of Cancer (EORTC) Quality of Life-Core 30 (QLQ-C30) and EORTC disease- or 
treatment-specific modules are cancer-specific questionnaires.38 Aspect-specific instruments 
evaluate specific aspects of HRQL.38 For instance, the Hospital Anxiety and Depression Scale 
(HADS) measures psychological health. In addition, except for these standardized 
questionnaires, HRQL can also be assessed using study-specific instruments or interviews.40 
2.2.1.2 HRQL after Esophageal Cancer Surgery 
Curatively intended surgery improves the chance of survival but entails substantially negative 
impacts on HRQL, especially within the first 12 months postoperatively.1,2,26,40-46 One study 
has shown that a large proportion of patients experience early satiety, fatigue, depression, and 
fear of metastasis and death within 1 year after esophagectomy.47 For long-term HRQL, poor 
physical function, severe breathlessness, diarrhea, and reflux are reported at 3 years after 
surgery,41 even though most HRQL aspects have recovered to the preoperative level.41,44 
Moreover, compared with the age- and sex-adjusted reference population, patients report 
worse social and role functions, and more fatigue, nausea and vomiting, diarrhea, and appetite 
loss at 3 years after surgery.48 Furthermore, according to one Swedish population-based 
study, there is no clinically relevant improvement in any measured aspects of HRQL between 
5 and 10 years after esophageal cancer surgery, and compared with the reference population, 
10-year survivors have worse HRQL in all 25 measured aspects of HRQL, especially in 
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global quality of life, social function, role function, eating difficulty, reflux, appetite loss, and 
diarrhea.49 
Recovery of HRQL is not only related to patients’ subjective satisfaction with their daily life, 
but also associated with objective survival rate.50 It has been found that improvements in 
emotional function and physical function between pre-treatment and 6 months after treatment 
are related to better survival,50,51 while increased fatigue and pain are associated with higher 
mortality.51 In addition, HRQL at 6 months after surgery for esophageal cancer significantly 
predicts all-cause mortality.52 
A large number of studies have investigated risk factors for poor HRQL.25,34,46,53-55 Patients 
with esophageal squamous cell carcinoma, with tumor located in the middle or upper 
esophagus, and with advanced tumor stage (III-IV) are more likely to have worse HRQL.53 
With regards to surgical approach, patients undergoing minimally invasive operation tend to 
have better physical function and global quality of life as well as less fatigue and pain at 3 
months postoperatively compared to patients with open esophagectomy.34 Also, transhiatal 
esophagectomy is associated with better activity levels and fewer physical symptoms at 3 
months post-surgery compared with transthoracic esophagectomy.46 However, no differences 
persist in the longer term.34,46,56 In addition, patients receiving a cervical anastomosis have 
better physical function, social function and global health status as well as less reflux-related 
symptoms like insomnia than patients receiving a intrathoracic anastomosis.54 Compared to 
patients without major postoperative complications, patients with major postoperative 
complications report more dyspnea, fatigue, and eating restrictions.25 Patients with 
comorbidity are prone to have compromised cognitive function, appetite loss, choking, and 
coughing than those with stable health status from 3 to 5 years post-surgery.55 Additionally, 
eating difficulty is related to worse HRQL in several aspects up to 10 years after surgery.57  
2.2.2 Anxiety and Depression 
2.2.2.1 Overview  
Diagnosed with a life-threatening esophageal cancer, undergoing an extensive 
esophagectomy, experiencing impaired HRQL, and facing a long convalescence are 
traumatic stressors for patients with esophageal cancer, which could trigger strong emotional 
responses. Anxiety and depression are two common emotional responses to stressors. 
Anxiety evoked by stressors is state anxiety, which manifests as being anxious, worried, 
irritable, fearful, and vigilant. Anxiety is an instinctively adaptive and protective response to 
danger, which helps to increase arousal level and promote defensive actions.58 However, 
excessive anxiety is a pathologically maladaptive response that weakens our ability to cope 
with the changing environment and could cause autonomic dysfunction.58 Depression caused 
by stressors is called exogenous depression, which manifests as anhedonia, neurovegetative 
symptoms (e.g., anorexia, insomnia, fatigue, and inattention), and somatic disturbances.58 It 
 
8 
usually further results in behavior disorders, like retreat from social and physical activities, 
diminished self-esteem, being occupied by a strong feeling of helplessness and worthlessness, 
or even suicide.58 
2.2.2.2 Anxiety and Depression after Esophageal Cancer Surgery 
High prevalence of anxiety and depression disorders have been found both before and after 
esophageal cancer surgery. A longitudinal study assessing anxiety and depression by HADS 
has shown that 33% of patients have anxiety disorders before esophagectomy, 28% at 6 
months and 37% at 12 months postoperatively.59 In contrast to the stable trend of anxiety, 
prevalence of depression disorders increases over time, from 20% prior to surgery to 27% at 
6 months and 32% at 12 months after surgery.59 One study following up patients for a median 
of 45 months after esophageal cancer diagnosis has found that 36% and 24% of patients have 
probable anxiety and depression, respectively.60 In addition, within 1 year after esophageal 
cancer surgery, 13.9% of patients have recorded psychiatric diagnosis or prescription in the 
British hospital and primary care databases.61 Within 2 years after esophageal cancer surgery, 
32.3% of patients without psychiatric histories are newly prescribed psychotropic drugs based 
on the data from the Swedish nationwide health registers.62 
There are some risk factors for developing anxiety and depression disorders after esophageal 
cancer surgery. Younger age, female sex, living alone, lower education level, histology of 
squamous cell carcinoma, postoperative complications and symptoms, and poor physical 
function have been found to be related to the development of anxiety and/or depression 
disorders.59,62-64 Also, anxiety and depression are associated with patients’ illness perception, 
which is an individual explanation for or perception of their illness including the timeline of 
the disease (chronic/acute/cyclical), personal control, treatment control, consequences, 
causes, and illness coherene.60 In addition, patients with negative coping strategies are more 
likely to develop anxiety and depression.60 
2.3 DISPOSITIONAL OPTIMISM 
2.3.1 Overview  
Dispositional optimism is individuals’ generalized expectancies for their future.65 People with 
higher dispositional optimism usually believe good things are going to happen, while people 
who are less optimistic or pessimistic expect the opposite.65 
Dispositional optimism is a personality trait that remains relatively stable without 
manipulation.66-69 Genetic influence accounts for 25-36% variation in dispositional optimism, 
which partly determines its stability.70,71 Other factors especially growth experience during 
childhood such as parents’ socioeconomic status and maternal child-rearing attitudes are 
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predictors of dispositional optimism,72,73 and the unchangeable nature of these factors in 
adulthood also partly explains the stability. However, it is also reported that dispositional 
optimism increases with the accumulation of individual’s social resources.74 In addition, 
dispositional optimism is modifiable via psychological interventions.75 
Until now, there is no universal agreement regarding the dimensionality of dispositional 
optimism. Some researchers view optimism and pessimism as one bipolar dimension, while 
some argue that optimism and pessimism are two separate dimensions. Practically speaking, 
everyone ranks in somewhere between extremely optimistic and extremely pessimistic, and 
there is no clear cut-off that separates people into either group.65 Thus, the assumption of one 
bipolar dimension may have a stronger theory base. However, when using Life Orientation 
Test (LOT) or Life Orientation Test-Revised (LOT-R) to measure dispositional optimism, it 
has been widely reported that two dimensions existed.76-81 The positively worded items and 
the negatively worded items measure different dimensions, namely, optimism and pessimism, 
respectively.76-81 In addition, some studies reported dissimilar predictive effects of optimism 
and pessimism,78,82 and being less pessimistic did not equal to being optimistic.78,82 On the 
other hand, some researchers argued that the two observed dimensions are artificial due to the 
method factor related to wording.83-89 Given that there is no consensus, researchers are 
encouraged to examine the structure when using LOT or LOT-R.90 
2.3.2 Predictive Effects of Dispositional Optimism  
Dispositional optimism as a personality trait is an important factor in the response to 
stressors. Previous studies conducted in different contexts have shown that less optimistic 
people are more likely to develop psychological distress and suffer from worse HRQL.91-105 
However, the associated HRQL aspects were not consistent across studies.96,99-105 In addition, 
higher dispositional optimism has been found to be related to better physical health including 
better overall survival and lower cause-specific (e.g., cardiovascular disease, cancer, and 
infection) mortality among general population, elderly population, and patients with some 
subtypes of cancer (e.g., recurrent or metastatic cancer treated with palliative radiation, head 
and neck cancer, and ovarian cancer).106-118 However, such significant associations were not 
observed among patients with metastatic colorectal cancer and patients with non-small cell 
lung cancer.119,120 Given the absence of previous studies among patients with esophageal 
cancer, it remains unclear whether these predictive effects of dispositional optimism exist in 
this population.  
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3 RESEARCH AIMS 
The overarching aim of this thesis was to investigate the potential roles of psychological 
factors especially dispositional optimism on survivorship after surgery for esophageal cancer. 
The specific aims of the included four studies were to investigate:  
⚫ The potential association between dispositional optimism and postoperative 
psychological distress after surgery for esophageal cancer (Study I); 
 
⚫ The potential effect of dispositional optimism on HRQL after surgery for esophageal 
cancer (Study II); 
 
⚫ The associaiton between psychological distress and HRQL after surgery for esophageal 
cancer (Study III); 
 
⚫ The influence of dispositional optimism on survival after surgery for esophageal cancer 





4 MATERIALS AND METHODS 
4.1 OVERVIEW 
Table 1. The overview of materials and methods used in studies I-IV 
 Study I Study II Study III Study IV 
Design Longitudinal study Cohort study 
Data source A Swedish nationwide cohort entitled “Oesophageal Surgery on Cancer 
Patients - Adaptation and Recovery (OSCAR)”. It contains patient-reported 
outcomes and data from medical charts and Swedish national registers. 
Population  Swedish residents undergoing surgery for esophageal cancer  
Included 
surgery period  
Jan 1, 2013 to Feb 28, 2018 Jan 1, 2013 to Dec 
31, 2019 
Follow-up time 
points/ period  
1, 1.5, and 2 years after esophageal cancer surgery Jan 1, 2014 to Dec 
31, 2020 










HRQL HRQL All-cause mortality  







































regression model  
Cox proportional 
hazards regression  
HRQL: Health Related Quality of Life. Jan: January. Feb: February. Dec: December.  
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4.2 DATA SOURCES 
Data for the four studies included in this thesis were from a prospective, Swedish nationwide, 
and population-based cohort study entitled “Oesophageal Surgery on Cancer patients - 
Adaptation and Recovery (OSCAR)”. 
4.2.1 The OSCAR Study  
The OSCAR study includes Swedish-speaking patients without cognitive impairment who 
underwent curatively intended surgery for esophageal cancer between January 1, 2013 and 
June 30, 2020 in Sweden and had survived for 1 year after surgery. Eligible patients were 
identified by contacting pathology departments at eight hospitals performing esophageal 
cancer surgery in Sweden.121 At around 1 year after surgery, each eligible patient’s vital 
status was checked based on the information from the Swedish Total Population Register, 
which contains fundamental information such as births, domestic and foreign relocations, and 
death about the Swedish residents.122 Later, the project coordinator sent the description of the 
OSCAR study together with an invitation letter to survivors by post followed by a telephone 
call.121 If patients had agreed to participate in the OSCAR study, a research nurse visited 
patients and conducted a face-to-face semi-structured interview containing both 
predetermined questions and open-ended questions. For the predetermined self-reported 
questionnaires, patients completed them on a touch screen tablet computer. The whole 
interview followed a predefined guidebook. In addition, patients were/will be followed up 
further at 1.5, 2, 2.5, 3, 4, 5, 8, and 12 years after surgery. Studies included in this thesis used 
data from three follow-up time points, 1, 1.5, and 2 years after surgery, and the 1.5- and 2-
year follow-up data were collected via mailing paper questionnaires.   
Sociodemographic data such as age, sex, cohabitation status, and education level were 
retrieved from the Longitudinal Integrated Database for Health Insurance and Labor Market 
Studies.123 Clinical data were extracted from medical records, which were obtained from the 
hospitals where patients underwent surgery and oncological treatments. All medical records 
were reviewed by two researchers following a predefined protocol.121 The clinical variables 
used in this thesis include weight, neoadjuvant therapy, histology, pathological tumor stage, 
resection margin status, surgical approach, postoperative complication, and comorbidity. 
Information on comorbidity was also collected from the Swedish Patient Register124 and the 
Swedish Cancer Register125. Linkages of individuals’ data between registers, medical records, 
and follow-up questionnaires were obtained through the unique personal identity number 




4.2.2.1 Life Orientation Test-Revised (LOT-R) 
LOT-R is a commonly used scale to measure dispositional optimism.66 This scale consists of 
three positively worded items, three negatively worded items, and four filler items.66 
Respondents are asked to indicate the extent of their agreement on each five-point Likert 
item, ranging from 0 “Strongly disagree” to 4 “Strongly agree”.66 There is an ongoing debate 
about the dimensionality of the LOT-R scale. It is originally treated as a unidimensional 
scale,66 where the negatively worded items are reversed prior to scoring and all items are 
loaded on one general factor representing dispositional optimism.66 However, some studies 
have found that a two-factor model positing that positively worded items measure optimism 
while negatively worded items measure pessimism fit the data better.78-81 Nevertheless, given 
that this scale has both positively and negatively worded items, some researchers argued that 
the identified two factors might be due to method effect associated with wording.87-89 
The Swedish version of LOT-R scale consists of six items where the four filler items have 
been removed.126 Given that no psychometric studies for LOT-R scale have been conducted 
among patients with esophageal cancer, in study I included in this thesis, we conducted a 
series of confirmatory factor analyses to examine the dimensionality of LOT-R scale based 
on the data from the OSCAR study. The model assuming one general factor on which all six 
items load and one method factor which includes the three negatively worded items showed 
the best fit. However, in this best-fit model, the loading of the first negatively worded item 
was negative even though its score has been reversed to account for the negative wording. 
Moreover, the distribution of patients’ responses to this item was bimodal. These suggest that 
a substantial proportion of patients may have misread the wording direction. Thus, we 
removed the first negatively worded item and adopted the model assuming one factor (i.e., 
dispositional optimism) with correlated errors between the rest two negatively worded items. 
The McDonald's omega estimating internal reliability was 0.49 with 95% bootstrapped 
confidence interval (CI) 0.31-0.62.  
4.2.2.2 Hospital Anxiety and Depression Scale (HADS)  
HADS is a well-validated and widely used instrument.127,128 It consists of two subscales 
measuring anxiety and depression respectively.127,128 Each subscale contains seven items and 
each item is scored on a four-point Likert scale ranging from 0 to 3, with a higher score 
representing a heavier burden of anxiety or depression.127,128 In most studies, for both 
subscales, a score of 7 or less is considered as non-case; a score of 8-10 is treated as 
borderline case and a score of 11 or more is regarded as definite case.127 Given that anxiety 
and depression frequently coexist,129 in this thesis, we regarded patients scoring 8 or more on 
either subscale as having clinically significant psychological distress. In addition, based on 
the OSCAR data, the internal reliability estimated by Cronbach’s alpha for the anxiety and 
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depression subscales were 0.83 and 0.74, respectively. The time frame covered by the HADS 
is the past week.127,128 
4.2.2.3 EORTC QLQ-C30  
The European Organization for Research and Treatment of Cancer Quality of Life-Core 30 
(EORTC QLQ-C30) is a well-validated and widely used questionnaire measuring HRQL 
among patients with cancer in general.130 This multidimensional questionnaire contains 30 
items, which comprise five functional subscales (physical, role, emotional, social, and 
cognitive), three symptom subscales (fatigue, pain, and nausea/vomiting), six single items 
(dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulty), and one 
global health status/quality of life subscale.130 All items are scored on a four-point Likert 
scale ranging from 1 “Not at all” to 4 “Very much”, except for the global health status/quality 
of life subscale, which ranges from 1 “Very poor” to 7 “Excellent”.130 The time frame for 
EORTC QLQ-C30 is the past week.130 
According to the EORTC Scoring Manual, the raw score for each subscale is the mean of its 
component items.131 All raw scores are transformed to a linear scale ranging from 0 to 100.131 
A higher score represents better function and global health status/quality of life or a heavier 
symptom burden.131 Based on the transformed scores, a single summary score for the EORTC 
QLQ-C30 can be calculated by averaging all subscales and single items except for the global 
health status/quality of life subscale and the single item regarding financial difficulty.132  
4.2.2.4 EORTC QLQ-OG25 
The European Organization for Research and Treatment of Cancer Quality of Life-Esophago-
Gastric cancer module 25 (EORTC QLQ-OG25) is a validated 25-item questionnaire 
measuring HRQL among patients with esophageal or gastric cancer.133 This questionnaire 
includes six symptom subscales (dysphasia, eating difficulty, reflux, odynophagia, pain and 
discomfort, and anxiety) and ten single items (eating in front of others, dry mouth, trouble 
with taste, trouble with swallowing saliva, choked when swallowing, trouble with coughing, 
trouble with talking, worry about weight loss, self-doubt regarding body image, and hair 
loss).133 Similar to the EORTC QLQ-C30, all items in the EORTC QLQ-OG25 are graded on 
a four-point Likert scale ranging from 1 “Not at all” to 4 “Very much”,133 and the raw score 
for each subscale is the mean of its component items.131 All raw scores are transformed to a 





4.3 STUDY DESIGN 
Study I, II, and III are nationwide population-based longitudinal studies, which included 
patients who underwent esophageal cancer surgery between January 1, 2013 and February 
28, 2018 in Sweden. Patients were followed up repeatedly at 1, 1.5, and 2 years after surgery. 
The processes of patient inclusion in study I, II, and III are presented in Figure 2.  
 
Figure 2. Flowchart of patient inclusion process in Study I, II, and III. 
 
18 
Study IV is a nationwide population-based prospective cohort study, which included patients 
who underwent esophageal cancer surgery between January 1, 2013 and December 31, 2019 
in Sweden. Patients were followed up until the date of death or until December 31, 2020, 
whichever occurred first. Figure 3 shows the process of patient inclusion in study IV. 
 





4.3.1 Study I 
4.3.1.1 Study aims and cohort 
This longitudinal study investigated the trajectory of clinically significant psychological 
distress from 1 to 2 years after surgery for esophageal cancer and examined whether 
dispositional optimism predicted this trajectory. Patients who underwent esophageal cancer 
surgery between January 1, 2013 and February 28, 2018 in Sweden and were alive at 1 year 
postoperatively were eligible to be included. Patients lacking valid contact information, died 
within 2 years after surgery, with psychiatric history, diagnosed as dysplasia by pathological 
examination, and with missing data in the independent variable (LOT-R scale) or covariates 
were excluded. 
4.3.1.2 Exposure and outcome 
Dispositional optimism was assessed at 1 year after surgery using the LOT-R scale. 
Psychological distress was measured at 1, 1.5, and 2 years after esophageal cancer surgery 
using the HADS. Patients scoring 8 or more on either the anxiety or the depression subscale 
were regarded as having clinically significant psychological distress.  
4.3.1.3 Statistical analysis 
The LOT-R sum score between patients with different characteristics were compared using 
Student’s t-test or ANOVA. The outcome, clinically significant psychological distress, was 
treated as a binary variable. Latent growth curve model with maximum likelihood estimator 
and logit link was used to investigate the trajectory of postoperative psychological distress 
and to examine the predictive effect of dispositional optimism. Random intercept model with 
linear slope was chosen because it fit the data best. When examining the predictive effect of 
dispositional optimism. Three nested models with adjustment for covariates were used. The 
first model was a crude model. The second model adjusted for previously identified 
confounders including age, sex, cohabitation status, and education level. The third model 
further adjusted for potential but unidentified confounders including comorbidity, 
neoadjuvant therapy, tumor stage, histology, and postoperative complications. The second 
and the third model were compared using the likelihood ratio test. In the main analysis, 
dispositional optimism was represented by the LOT-R sum score, and in the sensitivity 
analysis, it was represented by a latent (i.e., error free) factor. 
4.3.2 Study II  
4.3.2.1 Study aims and cohort 
This longitudinal study examined whether higher dispositional optimism predicted better 
HRQL after surgery for esophageal cancer. Patients who underwent esophageal cancer 
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surgery between January 1, 2013 and February 28, 2018 in Sweden and were alive at 1 year 
postoperatively were eligible to be included. Patients who were uncontactable, died before 
the 2-year follow-up, had histories of psychiatric disorders, with dysplasia diagnosed by 
pathological examination, and with missing data in the independent variable (LOT-R sum 
score) or covariates were excluded. 
4.3.2.2 Exposure and outcome 
The exposure was dispositional optimism, which was measured at 1 year after surgery using 
the LOT-R scale. A higher sum score of LOT-R represents higher dispositional optimism. 
The outcome was HRQL, which was measured repeatedly at 1, 1.5, and 2 years after surgery 
using the EORTC QLQ-C30 and EORTC QLQ-OG25. All HRQL scores were transformed 
to a linear score of 0-100.  
4.3.2.3 Statistical analysis  
The sum score of LOT-R scale between patients with different sociodemographic and clinical 
characteristics were compared using Student’s t-test or ANOVA. Based on the quartile of the 
LOT-R sum score, patients were classified into four subgroups with hierarchical dispositional 
optimism level: very low, moderately low, moderately high, and very high dispositional 
optimism. Linear mixed effects model was used to compare the mean score difference of 
HRQL between the four patient subgroups. Ten covariates were included in the model: 
assessment time point, age, sex, cohabitation status, education level, comorbidity, tumor 
stage, histology, postoperative complications, and weight change after surgery. In addition, 
an interaction between the exposure (dispositional optimism) and assessment time point was 
included in the model and was tested by the Wald test.  
Given that the outcome (HRQL) contains several aspects, in order to minimize the type I 
error (false positive), the significance testing for the adjusted mean score difference of HRQL 
was performed only if the difference had clinical relevance. With regards to clinical 
relevance, the mean score difference for subscales and single items included in the EORTC 
QLQ-C30 has four grades:134 (1) trivial: circumstances unlikely to have any clinical 
relevance or where there was no difference, (2) small: subtle but clinically relevant, (3) 
medium: likely to be clinically relevant but to a lesser extent, and (4) large: unequivocal 
clinical relevance.134 In this study, we only considered medium and large differences as 
clinically relevant. For emotional function, summary score of the EORTC QLQ-C30, and all 
aspects in the EORTC QLQ-OG25, the adjusted mean score difference of 10 or more was 
regarded as clinically relevant.135 
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4.3.3 Study III 
4.3.3.1 Study aims and cohort 
This longitudinal study examined the potential association between clinically significant 
psychological distress and HRQL after surgery for esophageal cancer. Patients who 
underwent esophageal cancer surgery between January 1, 2013 and February 28, 2018 in 
Sweden and were alive at 1 year postoperatively were eligible to be included. Patients who 
were not contactable, survived less than 26 months after surgery, with histories of psychiatric 
disorders, with dysplasia diagnosed by pathological examination, and with missing data in the 
sociodemographic or clinical information were excluded.  
4.3.3.2 Exposure and outcome 
Psychological distress was measured by the HADS at 1, 1.5, and 2 years after surgery. It was 
treated as a binary variable where patients scoring 8 or more on either the anxiety or the 
depression subscale were regarded as having clinically significant psychological distress. 
HRQL was measured by the EORTC QLQ-C30 and EORTC QLQ-OG25 at 1, 1.5, and 2 
years after surgery. Raw scores for all HRQL aspects were transformed to a linear scale 
ranging from 0 to 100.  
4.3.3.3 Statistical analysis    
For each follow-up time point, the characteristics of patients with and without clinically 
significant psychological distress were compared using Fisher’s exact test. Fixed effects 
regression model and random effects model were used to examine the association between 
psychological distress and HRQL after surgery. Psychological distress was treated as a time-
varying independent variable. Follow-up time point and postoperative weight change were 
adjusted in both the fixed and the random effects models as time-varying covariates. An 
interaction between psychological distress and time was also included and was examined by 
the Wald test. In addition, several observed time-invariant covariates were adjusted in the 
random effects model, which included age at surgery, sex, cohabitation status, education 
level, comorbidity, tumor stage, histology, and postoperative complications.  
4.3.4 Study IV 
4.3.4.1 Study aims and cohort 
This prospective cohort study investigated whether higher dispositional optimism predicted 
lower all-cause mortality after surgery for esophageal cancer, and whether this association 
was modified by the pathological tumor stage and the COVID-19 pandemic. Patients who 
underwent esophageal cancer surgery between January 1, 2013 and December 31, 2019 in 
Sweden and had survived for 1 year after surgery were eligible. Patients who were 
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uncontactable, with psychiatric history, or with missing data were excluded. All patients were 
followed up until the date of death or until December 31, 2020, whichever occurred first.  
4.3.4.2 Exposure and outcome 
The exposure, dispositional optimism, was measured by the LOT-R scale at 1 year post-
surgery, and a higher sum score of LOT-R represents higher dispositional optimism. The 
outcome was all-cause mortality after surgery, and this information was obtained from the 
Swedish Total Population Register.  
4.3.4.3 Statistical analysis  
Multivariable cox proportional hazards regression was used to analyze the association 
between disposition optimism and postoperative all-cause mortality, and we calculated the 
hazard ratio (HR) with 95% CI for the all-cause mortality with one unit increase in the LOT-
R sum score. The time scale was time since surgery. Age at surgery, sex, education level, and 
cohabitation status were adjusted in the model because they are confirmed confounders. 
Seven factors including pathological tumor stage, comorbidity, neoadjuvant therapy, 
histology, postoperative complication, resection margin status, and surgical approach were 
considered as potential but unproven confounders. We selected these seven covariates based 
on stepwise forward selection. Only variables causing at least 10% change in the estimated 
HR for the exposure were included in the final multivariable cox model. However, none of 
them met this inclusion criteria.  
To assess the potential effect modification by pathological tumor stage and the COVID-19 
pandemic, we first added an interaction between the exposure (dispositional optimism) and 
each potential effect modifier (pathological tumor stage or the COVID-19 pandemic) 
separately into the multivariable cox regression model. Given that the results suggested that 
both factors could be effect modifiers, interactions among dispositional optimism, 
pathological tumor stage, and the COVID-19 pandemic were added. Furthermore, we 
conducted a subgroup analysis which limited the follow-up before the COVID-19 pandemic 
occurrence in Sweden (i.e., March 1, 2020), and examined the effect modification by 
pathological tumor stage via adding an interaction term between dispositional optimism and 
pathological tumor stage into the corresponding multivariable cox model.   
In addition, in order to account for the potential reverse causality that imminent death might 
affect dispositional optimism, we conducted a sensitivity analysis excluding patients who 
survived less than 2 months after the measurement of dispositional optimism, and all cox 
models were re-estimated. The proportionality assumption was tested in all cox models using 
Schoenfeld residuals and this assumption was met for all cox models.  
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4.4 ETHICAL CONSIDERATIONS   
Data for all studies included in this thesis were from the OSCAR study. The OSCAR study 
has been approved by the Regional Ethical Review Board in Stockholm, Sweden (diary 
number 2013/844–31/1) before its initiation. The description of the OSCAR study was sent to 
all eligible patients who were contactable, and signed written consent was collected before 
enrolling patient into the study. In addition, all patients were informed that they have rights 
and freedoms to withdraw their consents or drop out the study at any time without any risk of 
getting any punishment. After the enrollment, each participant was assigned a unique 
research number to make their personal identity number encrypted, so they cannot be 
identified by researchers and readers via scientific research work including study protocol, 
data analysis, and study results. Moreover, results generated from this thesis project were 
presented at an aggregate level rather than individual level, which further makes the 
individual identification impossible. In addition, data from Swedish registers were completely 
de-identified, and informed consent is not required for the register-based data according to the 
Swedish regulation. The original data of OSCAR study are stored in safe servers at 
Karolinska Institutet, and only the principal investigator and the data collection team have 
access to them. The electronic datasets are protected by passwords and only the data manager 




Study I, II, III, and IV included 192, 192, 180, and 335 patients, respectively. Table 2 
presents the characteristics of patients included in these four studies.  
Table 2. Characteristics of patients included in studies I-IV 
 Study I and II Study III Study IV 
Age     
 Mean ± Standard deviation 66.3 ± 8.5 66.4 ± 8.5 67.4 ± 8.2 
 Range  [38.2, 83.7] [38.2, 83.7] [34.9, 83.7] 
Sex    
 Female 28 (14.6) 26 (14.4) 31 (9.3) 
 Male 164 (85.4) 154 (85.6) 304 (90.8) 
Cohabitation status   
 Non-cohabitating 44 (22.9) 42 (23.3) 79 (23.6) 
 Cohabitating 148 (77.1) 138 (76.7) 256 (76.4) 
Education level   
 Nine-year compulsory school 48 (25.0) 44 (24.4) 82 (24.5) 
 Upper secondary school 85 (44.3) 81 (45.0) 159 (47.5) 
 Higher education 59 (30.7) 55 (30.6) 94 (28.1) 
Neoadjuvant therapy    
 Yes  158 (82.3) 33 (18.3) 265 (79.1) 
 No  34 (17.7) 147 (81.7) 70 (20.9) 
Surgical approach    
 Total minimally invasive esophagectomy 52 (27.1) 50 (27.8) 115 (34.3) 
 Hybrid minimally invasive esophagectomy 63 (32.8) 59 (32.8) 119 (35.5) 
 Open esophagectomy 77 (40.1) 71 (39.4) 101 (30.2) 
Pathological tumor stage   
 Tis–II 133 (69.3) 126 (70.0) 219 (65.4) 
 III–IV 59 (30.7) 54 (30.0) 116 (34.6) 
Tumor histology   
 Adenocarcinoma 163 (84.9) 151 (83.9) 279 (83.3) 
 Squamous cell carcinoma 29 (15.1) 29 (16.1) 51 (15.2) 
 Dysplasia  0 (0) 0 (0) 5 (1.5) 
Postoperative complications (Clavien–Dindo grade)   
 No complication 69 (35.9) 65 (36.1) 113 (33.7) 
 I–II 54 (28.1) 50 (27.8) 94 (28.1) 
 III–IV 69 (35.9) 65 (36.1) 128 (38.2) 
Charlson comorbidity index   
 0   94 (49.0) 87 (48.3) 142 (42.4) 
 1 60 (31.3) 55 (30.6) 112 (33.4) 
 ≥2 38 (19.8) 38 (21.1) 81 (24.2) 
Note. All values are numbers (percentages %) unless otherwise stated. 
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5.1 STUDY I 
Study I included 192 patients. Of these, 164 (85.4%) patients were male, and 148 (77.1%) 
patients were married/cohabitating. The age at surgery ranged from 38.2 to 83.7 years with a 
mean value of 66.3 years and a standard deviation of 8.5 years. The observed LOT-R sum 
score ranged from 6 to 20 with a mean value of 15.2 and a standard deviation of 3.0. LOT-R 
sum scores were comparable between patients with different characteristics. 
Among the included 192 patients, 170 patients filled in the 1.5-year follow-up questionnaires, 
and 156 patients filled in the 2-year follow-up questionnaires. At 1, 1.5, and 2 years after 
esophagectomy for cancer, 11.5% (22 out of 192), 18.8% (32 out of 170), and 25.0% (39 out 
of 156) patients reported clinically significant psychological distress, respectively (Figure 4).  
 
Figure 4. Number of patients with and without clinically significant psychological distress 
at 1, 1.5, and 2 years after surgery for esophageal cancer. 
The association between dispositional optimism and postoperative psychological distress was 
not modified by the assessment time point, and higher dispositional optimism at 1 year post-
surgery predicted a lower risk of reporting clinically significant psychological distress at 1, 
1.5, and 2 years after surgery for esophageal cancer (Figure 5). The results generated from the 
three nested models with hierarchical adjustments were similar (Table 3). The second model 
with adjustment for sociodemographic covariates might be the best model based on prior 
knowledge and the likelihood ratio test. Odds ratio of reporting clinically significant 
psychological distress was 0.56 (95% CI 0.40 to 0.79) for one unit increase in the LOT-R 




Figure 5. Estimated probability of reporting clinically significant psychological distress as 
a function of LOT-R sum score for three assessment time points after surgery for 
esophageal cancer.  
Note. LOT-R: Life Orientation Test-Revised. 
 
Table 3. Odds ratio of reporting clinically significant psychological distress for each unit 
increase in the LOT-R sum score among patients with esophageal cancer surgery  
 Crude model Model adjusted for 
previously identified 
confounders  
Model adjusted for both 
identified confounders and 
potential but unidentified 
confounders 
Odds ratio 
with 95% CI 
0.56 (0.40, 0.80)  0.56 (0.40, 0.79) 0.55 (0.39, 0.78) 
Note. LOT-R: Life Orientation Test-Revised. CI: confidence interval. Previously identified 
confounders include age, sex, cohabitation status, and education level. Potential but 
unidentified confounders include comorbidity, neoadjuvant therapy, tumor stage, histology, 
and postoperative complications. 
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5.2 STUDY II 
Study II included 192 patients with surgery for esophageal cancer. Of these, 170 patients 
filled in the 1.5-year follow-up questionnaires for HRQL, and 156 patients filled in the 2-year 
follow-up questionnaires for HRQL. The observed range of LOT-R sum score was 6 to 20, 
with a mean value of 15.2 and a standard deviation of 3.0. LOT-R sum scores were 
comparable between patients with different characteristics. Based on the quartile of LOT-R 
sum score, the included 192 patients were divided into four subgroups (Table 4).  
Table 4. LOT-R sum score for four patient subgroups with hierarchical dispositional 
optimism levels 
 Dispositional optimism level 
 Very low 
(n = 48) 
Moderately low 
(n = 51) 
Moderately high 
(n = 45) 
Very high 
(n = 48) 
LOT-R sum score 
Range  [6, 13] [14, 15] [16, 17] [18, 20] 
Mean ± SD 11.3 ± 1.6 14.5 ± 0.5 16.5 ± 0.5 18.9 ± 0.9 
Note. LOT-R: Life Orientation Test-Revised. SD: standard deviation. 
Over the three assessment time points, patients with moderately low dispositional optimism 
did not report clinically different HRQL in any aspects compared to patients with very low 
dispositional optimism. However, time-invariant, clinically relevant, and statistically 
significant differences were found in global health status/quality of life (adjusted mean score 
difference 10, 95% CI 4 to 17) and diarrhea (adjusted mean score difference -9, 95% CI -18 
to -1) between patients with moderately high dispositional optimism and patients with lower 
(moderately low and very low) dispositional optimism.  
Patients with very high optimism reported clinically relevantly better HRQL in several 
aspects including global health status/quality of life, emotional function, social function, pain, 
dyspnea, diarrhea, anxiety, dry mouth, trouble with taste, worry about weight loss, self-doubt 
about body image, and eating difficulty compared to patients with lower (moderately high, 
moderately low, and very low) dispositional optimism (Figure 6). Only the adjusted mean 
score difference in eating difficulty varied over the three assessment time points, while the 





Figure 6. Health related quality of life aspects with time-invariant and clinically relevant 
mean score differences between patients with very high dispositional optimism and patients 
with lower (very low/moderately low/moderately high) dispositional optimism over the 
three assessment time points (1, 1.5, and 2 years after surgery for esophageal cancer). 
Note. QL: global health status/quality of life; EF: emotional function; SF: social function; 
PA: pain; DY: dyspnea; DI: diarrhea; OGANX: anxiety; OGDM: dry mouth; OGTA: 
trouble with taste; OGWL: worry about weight loss; OGBI: self-doubt regarding body 
image.  
5.3 STUDY III 
Study III included 180 patients who underwent surgery for esophageal cancer and attended 
the interview at 1 year post-surgery. Of these, 154 (85.6%) patients were male, and 138 
(76.7%) patients were married/cohabitating. The age at surgery ranged from 38.2 to 83.7 
years with a mean value of 66.4 years and a standard deviation of 8.5 years. During the 
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follow-ups, 157 patients filled in the 1.5-year follow-up questionnaires, and 151 patients 
filled in the 2-year follow-up questionnaires. The proportions of patients who reported 
clinically significant psychological distress at 1, 1.5, and 2 years postoperatively were 10.6% 
(19 out of 180), 17.2% (27 out of 157), and 23.2% (35 out of 151), respectively. At each 
assessment time point, patients’ sociodemographic and clinical characteristics were 
comparable between those reporting clinically significant psychological distress and those 
without clinically significant psychological distress.  
Results from random effects models with adjustments for observed confounders showed that 
compared with patients having clinically significant psychological distress, patients without 
clinically significant psychological distress reported clinically relevant and statistically 
significant better HRQL in most aspects. However, after further adjusting for unmeasured 
time-invariant confounders via fixed effects regression model, mean score differences with 
clinical relevance and statistical significance were found in fewer aspects, which included 
emotional function, social function, cognitive function, global health status/quality of life, 
summary score of EORTC QLQ-C30, dyspnea, appetite loss, anxiety, eating difficulty, eating 
in front of others, trouble with taste, worry about weight loss, and self-doubt about body 
image. Among these aspects, the adjusted mean score differences in cognitive function, 
global health status/quality of life, EORTC QLQ-C30 summary score, appetite loss, trouble 
with taste, and self-doubt about body image varied over time (Table 5), while the adjusted 
mean score differences in other aspects were not modified by time (Figure 7).  
Table 5. Health related quality of life aspects with time-varying adjusted mean score 
differences between patients with clinically significant psychological distress and patients 
without clinically significant psychological distress 
 
Adjusted mean score difference (95% CI) 
1 year 1.5 years 2 years 
Cognitive function  -7 (-14, -0) -3 (-9, 3) -11 (-17, -6) 
Global health status/quality of life -5 (-15, 4) -13 (-22, 5) -20 (-28, -13) 
EORTC QLQ-C30 summary score  -8 (-13, -3) -8 (-12, -4) -14 (-18, -10) 
Appetite loss   6 (-6, 18) 7 (-3, 17) 26 (17, 35) 
Trouble with taste  -4 (-15, 7) 13 (3, 23) 5 (-4, 13) 
Self-doubt about body image  28 (17, 38) 23 (14, 32) 13 (5, 21) 
Note. Values are adjusted mean score differences with 95% confidence intervals (CIs) in 
parentheses, rounded up to the nearest integer. Values in bold have clinical relevance and 
statistical significance. EORTC QLQ-C30, European Organization for Research and 




Figure 7. Health related quality of life aspects with time-invariant adjusted mean score 
difference between patients with clinically significant psychological distress and patients 
without clinically significant psychological distress. 
Note. Values are adjusted mean score differences with 95% confidence intervals (CIs) in 
parentheses, rounded up to the nearest integer. Values in bold and the aspects marked by * 
have clinical relevance and statistical significance. EORTC QLQ-C30, European 
Organization for Research and Treatment of Cancer Quality of Life-Core 30; EORTC 
QLQ-OG25, European Organization for Research and Treatment of Cancer Quality of 
Life-Esophago-Gastric cancer module 25. 
5.4 STUDY IV 
Study IV included 335 patients. Of these, 304 (90.8%) patients were male, and 256 (76.4%) 
patients were married/cohabitating. The age at surgery ranged from 34.9 to 83.7 years with a 
mean value of 67.4 years and a standard deviation of 8.2 years. Most patients (89.6%) were 
enrolled in the study before the COVID-19 pandemic in Sweden, and 65.4% of patients had 
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esophageal tumor with pathological stage Tis-II. The observed LOT-R sum score ranged 
from 6 to 20 with a mean value of 15.2 and a standard deviation of 3.0. LOT-R sum scores 
were comparable between patients with different characteristics. 
Both pathological tumor stage and the COVID-19 pandemic potentially modified the 
association between dispositional optimism and all-cause mortality. The adjusted HR of all-
cause mortality was 0.89 (95% CI 0.81 to 0.98) for one unit increase in the LOT-R sum score 
among patients with early and intermediate tumor stage (Tis-II) and with follow-up period 
before the COVID-19 pandemic (Figure 8). However, this association was not statistically 
significant for patients with advanced tumor stage (III-IV) and/or during the COVID-19 
pandemic (Figure 8). The subgroup analysis limiting the follow-up before the COVID-19 
pandemic generated similar results as the analysis using the whole cohort, and higher 
dispositional optimism predicted lower all-cause mortality in patients with tumor staged Tis-
II (HR 0.89, 95% CI 0.81 to 0.98) but not in patients with tumor staged III-IV (HR 0.99, 95% 
CI 0.92 to 1.07). The sensitivity analysis excluding patients who died within 2 months after 
dispositional optimism measurement generated almost unchanged results as the main 
analysis. 
 
Figure 8. Hazard ratio (HR) and 95% confidence interval (CI) of all-cause mortality for 
one unit increase in the sum score of Life Orientation Test-Revised (LOT-R), with 




6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Study Design  
Studies included in this thesis were observational population-based longitudinal studies based 
on a nationwide and prospectively collected cohort. In general, the quality of evidence of 
cohort studies is weaker than meta-analyses, systematic reviews, and randomized controlled 
trials.136 Given that no original studies on the topics covered by this thesis have been 
conducted previously in patients with esophageal cancer, it was impossible to conduct a 
meta-analysis or systemic review focusing on this patient population. However, few studies 
on these topics have been performed among patients with other subtypes of cancer, and in the 
future, with the accumulation of original studies, systematic reviews or meta-analyses 
focusing on a wide range of cancers may be worth being conducted. A randomized controlled 
trial is usually more robust to make causal inference because, theoretically, an ideal 
randomization process will break the association between the exposure and potential 
confounders. However, the strict experimental setting in randomized controlled trials reduces 
the generalizability of the study findings. Furthermore, for the topics covered by this thesis, 
randomized controlled trials might be either difficult or unethical to be implemented; 
therefore, observational studies might be the optimal choice to start with.   
6.1.2 Internal Validity 
Internal validity refers to whether the inference is true for the source population (the 
population from which the study sample was drawn).137 The most common violations of 
internal validity include selection bias, information bias, and confounding.137  
6.1.2.1 Selection bias 
Selection bias can occur at the participant recruitment stage and/or due to loss to follow-up.137  
It implies that the association observed in the study sample is not the true association in the 
source population.137 It is also recognized as “collider bias” resulting from conditioning on 
the common effect of the exposure (or variables associated with the exposure) and the 
outcome (or variables associated with the outcome).138 It is difficult to use statistical methods 
to control for or quantify the selection bias, so it is important to think through potential 
selection bias during the study design phase and try to avoid it.  
The studies included in this thesis were population-based. We aimed to invite and include all 
1-year survivors who underwent esophageal cancer surgery during the specified time period 
in Sweden. This strategy reduced the risk of selection bias. However, not all invited patients 
agreed to participate in the study, and the association between exposure and outcome 
observed in the participants might be different from the corresponding association among the 
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non-participants, which threatens the validity. For example, patients with lower dispositional 
optimism and worse HRQL might tend to reject the study invitation, and this could lead to an 
underestimation of the observed association. However, the outcomes in this thesis were 
measured repeatedly after patient enrollment, which decreased the risk of selection bias 
caused by non-participation because it was less likely that future outcomes affected the 
choice of participation.   
Loss to follow-up may be the principal cause for potential selection bias in this thesis. Study 
I, II, and III were longitudinal studies, and dropouts happened during the follow-up, which 
caused missing data. In the analyses, we used maximum likelihood estimation assuming that 
missing data caused by dropouts or intermittent attendance were missing at random. 
However, it is possible that this missingness is actually missing not at random, which could 
lead to biased estimates. For example, patients with lower dispositional optimism and worse 
HRQL might be prone to skip the follow-up questionnaires or drop out the study, which 
could make the observed association underestimated. It is difficult to address the issue caused 
by missing not at random, and usually auxiliary data (such as variables correlated with 
reasons for dropout) and more complicated statistical models (such as joint models) are 
required.139,140 In study IV, information about the outcome, all-cause mortality, was collected 
from the Swedish Total Population Register, which has complete ascertainment of death.122 
Such complete follow-up minimized the risk of selection bias in this study.  
6.1.2.2 Information bias 
Bias resulted from measurement errors is called information bias.137 For discrete variables, 
measurement error is also called misclassification or classification error.137 When the 
misclassification of one variable (e.g., exposure, outcome, or confounder) does not depend on 
other variables, it is called nondifferential misclassification. Otherwise it is called differential 
misclassification.137 Most measurement errors in this thesis were likely to be nondifferential.   
In this thesis, one major concern regarding information bias is the measurement error in the 
LOT-R scale. We used LOT-R to measure dispositional optimism and treated it as a 
continuous exposure in study I and as a categorical exposure in study II. Random 
measurement errors in the continuous exposure could dilute the real association.141 In study I, 
except for using the observed sum score of LOT-R to present dispositional optimism, we also 
used a latent (i.e., error free) factor to represent it. Such a strategy helped to quantify the bias 
caused by this measurement error, and the standardized effect size was truly increased after 
removing the measurement error. However, when the exposure is a categorical variable, the 
direction of the potential bias resulted from measurement error is hard to be predicted.142 
Therefore, it is difficult to evaluate the potential effects caused by measurement errors in 
LOT-R in study II.     
In addition, we used HADS to measure psychological distress and treated it as a binary 
outcome in study I and as a binary exposure in Study III. The HADS is estimated to have 
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good reliability (i.e., low measurement error). Moreover, nondifferential misclassification of 
the binary exposure tends to bias the observed estimate towards the null,137 and 
nondifferential misclassification of the binary outcome usually biases the estimate towards to 
the null or increases the standard error of the estimate.137,141 Therefore, measurement errors in 
HADS cannot explain the observed significant associations but might explain those observed 
nonsignificant associations. In study II and III, we used EORTC QLQ-C30 and EORTC 
QLQ-OG25 to measure HRQL and treated HRQL as continuous outcome. Random 
measurement errors in the continuous outcome usually do not bias the point estimate but 
increase the standard error of the estimate.141 For the mean score difference in HRQL 
between different exposure groups, we emphasized its clinical relevance rather than its 
statistical significance, which alleviated the effects of measurement errors in HRQL 
measurements in these two studies. The outcome in study IV was all-cause mortality, and we 
obtained this information from the Swedish Total Population Register that has high validity 
and completeness. Thus, it was less likely that this information contained measurement 
errors. In addition, measurement errors could also exist in confounders. Independent 
nondifferential measurement errors in confounders could lead to residual confounding or 
even worse distorted effect modification.137 In this thesis, we collected sociodemographic and 
clinical covariates from national registers and medical charts that were reviewed by two 
clinicians independently, which minimized the risk of measurement errors to a large extent.  
6.1.2.3 Confounding 
Confounding is the bias that arises from the presence of the common cause of exposure and 
outcome.138 Confounders are factors that could help remove confounding.138 Failure to adjust 
for potential confounders could lead to a spurious observed association between the exposure 
and the outcome.137,138  
Residual confounding is an important issue that needs to be considered especially in 
observational studies.137 While selection bias and information bias can only be avoided via 
study design, confounding bias can be controlled via both study design and statistical 
analysis.137 In the four studies included in this thesis, we used multivariable statistical 
analysis to control for observed potential confounders. In study III, we took the advantage of 
longitudinal study design and used fixed effects regression model, which further adjusted for 
unmeasured time-invariant confounders.143 Overall, the relatively comprehensive data 
collected in the OSCAR study have enabled adjustments for most important confounders in 
this thesis. However, there is still a risk of residual confounding due to unmeasured 




6.1.3 Random Error 
Except for the systematic errors (selection bias, information bias, and confounding) that have 
been discussed above, another type of error damaging the accuracy of an estimate is random 
error.137 Significance testing is used to decide whether the observed association is solely due 
to random error.137 A computed quantity called P-value is compared with the predefined 
cutoff point called alpha (α) level.137 The alpha level is usually set at 0.05 by convention. The 
P-value is the probability of obtaining results equal to or more extreme than the results 
observed when the null hypothesis is true.137 If P < α, we say that the test is statistically 
significant at level α and reject the null hypothesis.137 Type I error (i.e., alpha error) occurs if 
the true null hypothesis is incorrectly rejected.137 In this thesis, the outcomes in study II and 
III were HRQL that contains many aspects, and thus multiple testing was required, which 
boosted the likelihood of type I error. To minimize the type I error, we only conducted 
significance testing for the aspects in which mean score difference had clinical relevance. In 
addition, type II error (i.e., beta error) occurs if the false null hypothesis is not rejected.137 
When the sample size is small, the risk of type II error becomes high because the study may 
have low power to detect the truly existed effect. In study I, II, and III, although the number 
of included patients were not many, each patient was measured repeatedly over time, which 
increased the total number of observations and thus boosted the statistical power. In study IV, 
we incorporated interaction terms in statistical models, and this study might be underpowered 
to detect interaction effects given that such an analysis requires large sample size.144 
However, in this study, we evaluated the interaction based on effect size instead of P-value, 
which minimized the risk of type II error. In addition, compared with P-value, it is more 
recommended to use confidence interval to account for random error. Confidence interval 
with 1-alpha (e.g., 95%) confidence level is a range of parameter values whose P-values 
exceed the specified alpha level (e.g., 0.05).137 We used 95% confidence interval throughout 
studies included in this thesis.  
6.1.4 External Validity 
External validity or generalizability refers to how well the inference could be generalized to 
other populations or settings.137 Internal validity is the prerequisite for external validity.137 
Studies included in this thesis are qualified for the evaluation of external validity given their 
overall good internal validity as discussed above. The four studies included in this thesis were 
Swedish nationwide population-based studies, which facilitate the generalizability. However, 
eligible patients in these four studies were those having survived at least 1 year after 
esophageal cancer surgery, and findings from this thesis should be generalized with great 
caution to patients surviving less than 1 year after surgery for esophageal cancer.  
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6.2 GENERAL DISCUSSION 
6.2.1 Study I, II, and IV 
Study I found that the proportion of patients self-reporting clinically significant psychological 
distress increased from 1 to 2 years after surgery for esophageal cancer and that more 
optimistic patients were less likely to report clinically significant psychological distress. 
Study II found that more optimistic patients reported better HRQL after surgery for 
esophageal cancer. Study IV further found that more optimistic patients had a better overall 
survival, but this association was only significant among patients with esophageal cancer 
staged Tis-II and when the follow-up was before the COVID-19 pandemic. 
In study I, 11.5% and 25.0% of patients reported clinically significant psychological distress 
at 1 and 2 years post-surgery, respectively. These proportions were similar with but a bit 
lower than the proportions presented by two previous studies with large sample sizes.61,62 One 
study based on the data from the British hospital and primary care databases has found that 
13.9% of patients had psychiatric diagnosis or prescription within 1 year after surgery for 
esophageal cancer,61 and the other study based on the data from the Swedish nationwide 
health registers has found that 32.3% of patients were newly prescribed psychotropic drugs 
within 2 years after esophageal cancer surgery.62 Several reasons might explain the minor 
inconsistencies between study I and previous studies. First, some patients refused to 
participate in the OSCAR study, and non-participants might suffer more from psychiatric 
disorders, which could result in underestimations of these proportions in study I. Second, 
study I only assessed anxiety and depression using the self-reported questionnaire HADS, 
while the previous two studies used comprehensive psychiatric diagnoses and/or prescriptions 
to identify psychiatric disorders. Also, the risk of misclassification might be higher when 
categorizing patients only based on self-reporting compared with based on clinical diagnosis 
and/or prescription, and most likely self-reporting would lead to underestimation.145 
Moreover, psychiatric drugs could be prescribed for purposes other than treating psychiatric 
disorders (e.g., antidepressants can be used for cancer pain),146 which could result in 
overestimation in previous studies. In addition, the previous two studies assessed cumulative 
incidences of psychiatric disorders within 1 and 2 years after esophageal cancer surgery, 
while Study I in this thesis assessed psychological distress at 1 and 2 years after surgery. 
However, the longitudinal trajectories found by study I and previous studies were the same, 
and that is that psychiatric disorders after esophageal cancer surgery increased over time.  
The increasing proportion of patients with clinically significant psychological distress over 
time suggests unmet needs for early detection and timely psychological support. Esophageal 
cancer surgery is a major procedure which removes part of or all esophagus and then 
reconstructs the digestive tract. Recovery and adaptation after esophageal cancer surgery is a 
long process. Postoperative symptoms and compromised functioning could exist until 10 
years after surgery.49 Moreover, patients may further develop new comorbidities due to 
increasing age and pre-existed risk factors related to esophageal cancer.4 Constantly exposed 
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to these stressors could lead to changes in glucocorticoid signalling and brain structure,147,148 
and thus further make patients vulnerable to psychological distress.148  
There are several potential mechanisms explaining the observed predictive effects of 
dispositional optimism on postoperative psychological distress, HRQL, and survival. Given 
that these results were from observational studies, residual confounding such as genetic 
factors70,149,150 and early life experience151 might cause spurious observed associations. 
However, these observed associations might also be causal, and several potential pathways 
could be involved. Previous studies have found that more optimistic people tend to adopt 
more effective coping strategies, adjust goals more efficiently, and receive more social 
support.152-159 Effective coping strategies are associated with less psychological distress and 
better HRQL.160-162 After esophageal cancer diagnosis and surgery, the feasibility of 
previously set goals may change, and efficient goal adjustments could help patients focus 
more on achievable goals and rapidly disengage from unattainable goals, thus leading to less 
psychological distress and better HRQL.163-165 Higher social support has been found to be 
related to better mental health, better HRQL, and better overall survival.166-168 Furthermore, 
more optimistic people are prone to have healthier lifestyles including smoking less, exercise 
more, and eat healthier,169 and thus might be less likely to develop comorbidities and more 
likely to have a better recovery after esophageal cancer surgery. In addition, people with 
higher dispositional optimism tend to have healthier levels in several aging-related 
biomarkers (e.g., telomere, interleukin-6, fibrinogen, homocysteine, and lipid profile) 
compared with less optimistic people,170-172 and thus might have a lower risk of dying from 
aging-related diseases and be more likely to have better overall survival. Additionally, given 
that psychological comorbidities and poor HRQL are risk factors for poor survival after 
esophageal cancer surgery,50-52,62 one potential pathway could also be that higher 
dispositional optimism led to less psychological distress and better HRQ, and the latter 
further contributed to better overall survival.   
In study I and II, we followed up patients who underwent surgery between January 1, 2013 
and February 28, 2018 in Sweden for two years, so the included follow-up periods ended 
approximately on February 29, 2020, while in study IV, the included follow-up period were 
until December 31, 2020. Given that only two cases of COVID-19 were reported in January 
and February, 2020 in Sweden,173 it is less likely that the COVID-19 pandemic had effects on 
the results of study I and II, and whether the results from these two studies could be 
generalized to the periods with and after the COVID-19 pandemic needs further 
investigation. In study IV, we examined the potential effect modification by the COVID-19 
pandemic, and found that the association between dispositional optimism and all-cause 
mortality was not statistically significant during the COVID-19 pandemic. However, given 
the rather small sample size and relatively short follow-up period during the COVID-19 
pandemic, this result was of low precision, and should be interpreted cautiously and 
examined further by studies with larger sample sizes. Nevertheless, it made conceptual sense 
that higher dispositional optimism no longer had protective effects on survival during the 
COVID-19 pandemic. Patients with cancer have higher risks for COVID-19 infection and its 
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adverse outcomes including death.174-176 Moreover, the postponements of routine health care 
and scheduled surgery during the COVID-19 pandemic173 may have further decreased the 
controllability of esophageal cancer, and thus patients could hardly prolong their lives via 
being optimistic. In addition, in study IV, we also found that the association between 
dispositional optimism and all-cause mortality was close to the null among patients with 
advanced tumor stage. This might also be because the prognosis for advanced esophageal 
cancer is much less controllable with 5-year survival rate less than 15%.2 
The observed predictive effects of dispositional optimism on postoperative psychological 
distress, HRQL, and survival may assist in identifying vulnerable patients with worse 
prognosis after surgery for esophageal cancer, thus contributing to the development of more 
tailored and timely interventions to improve postoperative survivorship. In addition, given 
that dispositional optimism is modifiable via psychological interventions including Best 
Possible Self exercise and cognitive behavior therapy,75 enhancing dispositional optimism 
may help improve prognosis after esophageal cancer surgery.  
6.2.2 Study III 
Study III found that clinically significant psychological distress was associated with worse 
HRQL after surgery for esophageal cancer. In this study, we used fixed effects regression 
model to control for all time-invariant covariates (no matter they were measured or not) and 
observed time-varying confounders.143 This method takes the advantage of longitudinal study 
design and, in essence, compares patients with themselves (i.e., compares patients’ status at 
later time points with their own status at earlier time points). Therefore, it removes the 
confounding due to time-invariant confounders, which enhances causal inference. However, 
there is still a risk of residual confounding resulted from unmeasured time-varying 
confounders. Furthermore, given that the independent variable (psychological distress) and 
the dependent variable (HRQL) were measured repeatedly at the same time points in this 
study, it is difficult to ascertain the direction of the potential causation between psychological 
distress and HRQL.  
In this study, after adjusting for all time-invariant covariates and observed time-varying 
confounders, we found that clinically significant psychological distress was associated with 
worse emotional function and social function, and more dyspnea, anxiety, eating difficulty, 
trouble with eating in front of others, and worry about weight loss. Given that these 
associations were not modified by time, the potential bias caused by time-varying 
confounders might not sufficiently explain these observed associations. In other words, these 
observed associations might be causal, even though we cannot determine the potential causal 
direction. It might be that clinically significant psychological distress caused worse emotional 
function and social function, and more worry about weight loss. However, it could also be 
that severe postoperative symptoms such as eating difficulty caused clinically significant 
psychological distress.  
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We also found time-varying associations between clinically significant psychological distress 
and cognitive function, global health status/quality of life, EORTC QLQ-C30 summary score, 
appetite loss, trouble with taste, and self-doubt about body image. Residual time-varying 
confounders such as cancer recurrence and postoperative adaptation might be potential 
explanations for these observed time-varying associations. In addition, the adjusted mean 
score difference in most of these aspects increased over time, from clinically irrelevant to 
clinically relevant. The increased associations might be because patients developed more 
severe psychological distress over time, and thus led to further deteriorated HRQL. However, 
it might also be the other way around, and that is that patients with constantly deteriorated 
HRQL were more likely to suffer from psychological distress.  
This study highlights the importance of timely and effective interventions to prevent 
psychological distress and to improve HRQL after esophageal cancer surgery, given that 
clinically significant psychological distress and worse HRQL might cause each other. In other 





⚫ From 1 year to 2 years after surgery for esophageal cancer, self-reported clinically 
significant psychological distress increased over time. 
 
⚫ Higher dispositional optimism predicted better HRQL and a lower risk of reporting 
clinically significant psychological distress after surgery for esophageal cancer. 
 
⚫ Postoperative psychological distress and HRQL were potentially causally associated, but 
the direction of the potential causation was uncertain.   
 
⚫ Higher dispositional optimism predicted better overall survial among patients with early 




8 POINTS OF PERSPECTIVE 
The predictive effects of dispositional optimism on postoperative psychological distress, 
HRQL and survival among patients with esophageal cancer surgery may help update the 
prognostic model and contribute to the development of personalized health care. Future 
studies with larger sample sizes are required to further validate these predictive effects. In 
addition, whether these predictive effects could be generalized to other populations is largely 
unknow, and related studies are warranted.  
Given that the observed predictive effects might be explained by residual confounding, 
whether these associations are causal or not need to be examined further in the future. If these 
associations are causal, it may be worth investigating the underlying mechanisms or 
pathways and especially identifying those easily modifiable mediators. In addition, given that 
dispositional optimism is potentially modifiable via psychological interventions,75 studies 
exploring whether increasing dispositional optimism could improve postoperative prognosis 
are also warranted.  
This thesis also found that postoperative psychological distress and worse HRQL might be 
causally associated. However, this potential causation identified in this thesis was cross-
sectional, and we cannot determine the direction of the potential causation. In the future, 
longitudinal studies using more complicated statistical models such as cross-lagged panel 
model might be useful to examine the potential causal direction. In addition, time-varying 
confounding is a threat to the potential causation identified in this thesis, and future studies 




I would like to thank all patients for their participation and their contribution in promoting the 
progress of medical science. I would also like to express my sincere gratitude to everyone 
who has given me support that made this thesis possible, including but not limited to:  
Pernilla Lagergren, my main supervisor. Thank you very much for offering me this precious 
opportunity to pursue my doctoral degree in your group and guiding me to the field of cancer 
epidemiology and survivorship. I am very grateful for your support, encouragement, trust, 
guidance, kindness, openness, and inclusiveness. You not only trained me on scientific 
research, but also taught me how to deal with difficulties and how to maintain a work-life 
balance. All of this makes my PhD journey become a wonderful experience which I will 
treasure forever. It is a great honor to have you as my supervisor! 
Anna Schandl, my co-supervisor. Thank you very much for always being supportive, 
conscientious, and considerate. Combining clinical work with research is not an easy thing, 
but you made it! You always give me your invaluable comments and suggestions efficiently, 
and have never missed any important meetings/seminars related to my doctoral education. 
Also, I highly appreciate all the encouragements and trusts that you have given to me! 
Erik Pettersson, my co-supervisor who joined this thesis project when I was struggling with 
the pessimistic feelings resulted from the scale measuring optimism. Your expertise in 
epidemiology, psychology, and statistics have guided me through the “darkness”. I greatly 
appreciate your extraordinary patience and generosity in sharing your professional answers to 
my “endless” questions, and I really enjoyed all the discussions we had, which extremely 
enlightened and inspired me! I look forward to continuing working with you in the future!  
Markar Sheraz, my co-supervisor. Thank you very much for always giving me your 
insightful feedbacks efficiently no matter how busy you are. I am very grateful for your 
encouragements and your efforts in boosting the visibility of our work on social media. 
Moreover, your genuine passion for clinical research and your diligence at work have 
impressed and inspired me a lot! 
Asif Johar, my informal co-supervisor, and statistician in our research group. Thank you 
very much for providing statistical support for my thesis project and giving me great 
guidance and supervision in statistics! Also, thank you for all those spontaneous jokes during 
meetings and fikas, which brought me lots of laughs and made statistics more interesting! 
Jesper Lagergren, thank you very much for providing such a collaborative, friendly, and 
inspiring work environment! Also, I am deeply impressed and inspired by your excellent 
leadership, immense passion for research, and enormous enthusiasm for ping-pong! 
Shaohua Xie, thank you very much for always sharing your invaluable academic and life 
experience openly when I need help. Your vast knowledge in epidemiology and statistics 
have impressed me, and I have learned a lot from you! All the best to you and your family!  
 
46 
My current and former coworkers/friends at Surgical Care Science and Upper 
Gastrointestinal Surgery research groups, many thanks for creating such a great work 
environment and inspiring me with your fantastic work! Special thanks to Giulia Marras, 
Karin Vikström, and Hanna Johans for support in administrative work! A big thanks to 
Poorna Anandavadivelan, my office mentor, for taking care of me when I was new to the 
office. Special thanks to Jiaojiao Zheng, Cecilia Haddad Ringborg, Kalle Mälberg, Zhao 
Cheng, Yunhe Gao, Qiaoli Wang, Eva Doorakkers, Giola Santoni, Huiting Tang, Dag 
Holmberg, Sirus Rabbani, Sandra Nielsen, Helen Rosenlund, Fredrik Mattsson, Joonas 
Kauppila, John Maret-Ouda, Manar Yanes, Eivind Gottlieb, Eivind Ness-Jensen, and 
Wenjing Tao, for all the chats, encouragements, support, and after-work activities!     
Many thanks to Karolinska Institutet and Department of Molecular Medicine and 
Surgery. Special thanks to Ann-Britt Wikström and Catharina Lavebratt for support!  
Hongyi Xu, my mentor, many thanks for your help and advice on my work and my life in 
Sweden! Jiayin Yuan, my informal mentor, thank you very much for recommending 
interesting movies to me and sharing enlightening stories/metaphors with me!     
Zhiping Hu, my master’s supervisor. Thank you for supporting me to pursue doctoral degree 
abroad and always providing generous help to me whenever I need. I am inspired by your 
expertise in clinical medicine especially in neurology, your kindness to patients and people 
around you, and your optimistic attitude to life. Wish you good health and greater success!  
Hu Yan, my psychology tutor. Thank you very much for inviting me to join your drawing 
psychoanalysis research when I was a medical student and introducing me to the field of 
psychology. I wish you all the best in your future endeavors! 
All my dear friends in China, Sweden, and other parts of the world (no one is listed here, 
but you are all in my heart), you are one of the great treasures in my life! I highly appreciate 
all the laughs, different visions, and strong support that you have brought/given to me. 
Special thanks to those who have accompanied and helped me during my life crisis.  
My parents, thank you so much for your unconditional love and support! Mommy, I know 
that you always want and was trying to give me the best things in the world, and you did! 
You have given me the best love in the world! Also, your hard-working spirit, empathy for 
others, and philosophy about life have given me strength to pursue the best things in life. I 
miss you so much and really wish that I could share all milestones in my life with you. But 
probably you knew all the answers because you always believe in me. Love you! Dad, thank 
you for helping me develop broad interests especially in reading! My uncles, cousins, and 
other relatives, thank you very much for all the love and support that you have given to me! 
My parents in law, thank you so much for your love and your incredibly strong support to 
me and my husband! 
Taimin, my soulmate. Thank you for always spoiling me and supporting me to pursue goals 




1. Kauppila JH, Mattsson F, Brusselaers N, Lagergren J. Prognosis of oesophageal 
adenocarcinoma and squamous cell carcinoma following surgery and no surgery in a 
nationwide Swedish cohort study. Bmj Open. 2018;8(5):e021495. 
2. Office for National Statistics. Cancer survival in England - adults diagnosed. 2019; 
https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditio
nsanddiseases/datasets/cancersurvivalratescancersurvivalinenglandadultsdiagnosed. 
Accessed Jun 27, 2021. 
3. Lagergren J, Smyth E, Cunningham D, Lagergren P. Oesophageal cancer. Lancet. 
2017;390(10110):2383-2396. 
4. Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer. Nat Rev Dis 
Primers. 2017;3:17048. 
5. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal 
cancer by histological subtype in 2012. Gut. 2015;64(3):381-387. 
6. Freedman ND, Park Y, Subar AF, et al. Fruit and vegetable intake and esophageal 
cancer in a large prospective cohort study. Int J Cancer. 2007;121(12):2753-2760. 
7. Freedman ND, Abnet CC, Leitzmann MF, et al. A prospective study of tobacco, 
alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol. 
2007;165(12):1424-1433. 
8. Islami F, Boffetta P, Ren JS, Pedoeim L, Khatib D, Kamangar F. High-temperature 
beverages and foods and esophageal cancer risk--a systematic review. Int J Cancer. 
2009;125(3):491-524. 
9. Yang CS, Sun Y, Yang Q, et al. Vitamin A and other deficiencies in Linxian, a high 
esophageal cancer incidence area in northern China. JNCI: Journal of the National 
Cancer Institute. 1984;73(6):1449-1453. 
10. Cooper SC, Day R, Brooks C, Livings C, Thomson CS, Trudgill NJ. The influence of 
deprivation and ethnicity on the incidence of esophageal cancer in England. Cancer 
Causes Control. 2009;20(8):1459-1467. 
11. Qu X, Ben Q, Jiang Y. Consumption of red and processed meat and risk for 
esophageal squamous cell carcinoma based on a meta-analysis. Ann Epidemiol. 
2013;23(12):762-770 e761. 
12. Guo F, Liu Y, Wang X, et al. Human papillomavirus infection and esophageal 
squamous cell carcinoma: a case-control study. Cancer Epidemiol Biomarkers Prev. 
2012;21(5):780-785. 
13. Spechler SJ, Souza RF. Barrett's esophagus. N Engl J Med. 2014;371(9):836-845. 
14. Cook MB, Corley DA, Murray LJ, et al. Gastroesophageal reflux in relation to 
adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and 
Esophageal Adenocarcinoma Consortium (BEACON). PloS one. 2014;9(7):e103508. 
15. Cook MB, Kamangar F, Whiteman DC, et al. Cigarette smoking and 
adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis 




16. Stein DJ, El-Serag HB, Kuczynski J, Kramer JR, Sampliner RE. The association of 
body mass index with Barrett's oesophagus. Aliment Pharmacol Ther. 
2005;22(10):1005-1010. 
17. Jiao L, Kramer JR, Rugge M, et al. Dietary intake of vegetables, folate, and 
antioxidants and the risk of Barrett's esophagus. Cancer Causes Control. 
2013;24(5):1005-1014. 
18. Jiao L, Kramer JR, Chen L, et al. Dietary consumption of meat, fat, animal products 
and advanced glycation end-products and the risk of Barrett's oesophagus. Aliment 
Pharmacol Ther. 2013;38(7):817-824. 
19. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN 
estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a 
cancer journal for clinicians. 2021. 
20. Wang Q-L, Xie S-H, Wahlin K, Lagergren J. Global time trends in the incidence of 
esophageal squamous cell carcinoma. Clin Epidemiol. 2018;10:717-728. 
21. Trivers KF, Sabatino SA, Stewart SL. Trends in esophageal cancer incidence by 
histology, United States, 1998-2003. Int J Cancer. 2008;123(6):1422-1428. 
22. Edgren G, Adami HO, Weiderpass E, Nyren O. A global assessment of the 
oesophageal adenocarcinoma epidemic. Gut. 2013;62(10):1406-1414. 
23. Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the 
esophagus and esophagogastric junction: application to clinical practice. Ann 
Cardiothorac Surg. 2017;6(2):119-130. 
24. Markar SR, Karthikesalingam A, Thrumurthy S, Low DE. Volume-outcome 
relationship in surgery for esophageal malignancy: systematic review and meta-
analysis 2000-2011. Journal of gastrointestinal surgery : official journal of the 
Society for Surgery of the Alimentary Tract. 2012;16(5):1055-1063. 
25. Derogar M, Orsini N, Sadr-Azodi O, Lagergren P. Influence of Major Postoperative 
Complications on Health-Related Quality of Life Among Long-Term Survivors of 
Esophageal Cancer Surgery. J Clin Oncol. 2012;30(14):1615-1619. 
26. Rutegard M, Charonis K, Lu Y, Lagergren P, Lagergren J, Rouvelas I. Population-
based esophageal cancer survival after resection without neoadjuvant therapy: an 
update. Surgery. 2012;152(5):903-910. 
27. Rustgi AK, El-Serag HB. Esophageal carcinoma. N Engl J Med. 2014;371(26):2499-
2509. 
28. Allum WH, Blazeby JM, Griffin SM, et al. Guidelines for the management of 
oesophageal and gastric cancer. Gut. 2011;60(11):1449-1472. 
29. Gottlieb-Vedi E, Kauppila JH, Malietzis G, Nilsson M, Markar SR, Lagergren J. 
Long-term Survival in Esophageal Cancer After Minimally Invasive Compared to 
Open Esophagectomy: A Systematic Review and Meta-analysis. Ann Surg. 
2019;270(6):1005-1017. 
30. Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid Minimally Invasive 
Esophagectomy for Esophageal Cancer. N Engl J Med. 2019;380(2):152-162. 
31. Straatman J, van der Wielen N, Cuesta MA, et al. Minimally Invasive Versus Open 
Esophageal Resection: Three-year Follow-up of the Previously Reported Randomized 
Controlled Trial: the TIME Trial. Ann Surg. 2017;266(2):232-236. 
 
 49 
32. Biere SS, van Berge Henegouwen MI, Maas KW, et al. Minimally invasive versus 
open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, 
randomised controlled trial. Lancet. 2012;379(9829):1887-1892. 
33. Maas KW, Cuesta MA, van Berge Henegouwen MI, et al. Quality of Life and Late 
Complications After Minimally Invasive Compared to Open Esophagectomy: Results 
of a Randomized Trial. World J Surg. 2015;39(8):1986-1993. 
34. Kauppila JH, Xie S, Johar A, Markar SR, Lagergren P. Meta-analysis of health-
related quality of life after minimally invasive versus open oesophagectomy for 
oesophageal cancer. The British journal of surgery. 2017;104(9):1131-1140. 
35. Shapiro CL. Cancer Survivorship. N Engl J Med. 2018;379(25):2438-2450. 
36. American Society of Clinical Oncology. What is survivorship? 2021; 
https://www.cancer.net/survivorship/what-survivorship. Accessed November 8, 2021. 
37. Mullan F. Seasons of survival: reflections of a physician with cancer. N Engl J Med. 
1985;313(4):270-273. 
38. Fayers PM. Quality of life : the assessment, analysis, and reporting of patient-
reported outcomes. 3rd ed. ed: Chichester, West Sussex, England : Wiley Blackwell; 
2016. 
39. Osoba D. Translating the science of patient-reported outcomes assessment into 
clinical practice. Journal of the National Cancer Institute Monographs. 2007(37):5-
11. 
40. Djärv T, Lagergren P. Quality of life after esophagectomy for cancer. Expert Review 
of Gastroenterology & Hepatology. 2012;6(1):115-122. 
41. Lagergren P, Avery KN, Hughes R, et al. Health-related quality of life among patients 
cured by surgery for esophageal cancer. Cancer. 2007;110(3):686-693. 
42. Avery KN, Metcalfe C, Barham CP, Alderson D, Falk SJ, Blazeby JM. Quality of life 
during potentially curative treatment for locally advanced oesophageal cancer. The 
British journal of surgery. 2007;94(11):1369-1376. 
43. Viklund P, Wengström Y, Rouvelas I, Lindblad M, Lagergren J. Quality of life and 
persisting symptoms after oesophageal cancer surgery. European Journal of Cancer. 
2006;42(10):1407-1414. 
44. Blazeby JM, Farndon JR, Donovan J, Alderson D. A prospective longitudinal study 
examining the quality of life of patients with esophageal carcinoma. Cancer. 
2000;88(8):1781-1787. 
45. Donohoe CL, McGillycuddy E, Reynolds JV. Long-term health-related quality of life 
for disease-free esophageal cancer patients. World J Surg. 2011;35(8):1853-1860. 
46. de Boer AG, van Lanschot JJ, van Sandick JW, et al. Quality of life after transhiatal 
compared with extended transthoracic resection for adenocarcinoma of the esophagus. 
J Clin Oncol. 2004;22(20):4202-4208. 
47. Verschuur EM, Steyerberg EW, Kuipers EJ, et al. Experiences and expectations of 
patients after oesophageal cancer surgery: an explorative study. Eur J Cancer Care 
(Engl). 2006;15(4):324-332. 
48. Djärv T, Lagergren J, Blazeby JM, Lagergren P. Long-term health-related quality of 
life following surgery for oesophageal cancer. Brit J Surg. 2008;95(9):1121-1126. 
 
50 
49. Schandl A, Lagergren J, Johar A, Lagergren P. Health-related quality of life 10 years 
after oesophageal cancer surgery. European journal of cancer (Oxford, England : 
1990). 2016;69:43-50. 
50. Blazeby JM, Brookes ST, Alderson D. The prognostic value of quality of life scores 
during treatment for oesophageal cancer. Gut. 2001;49(2):227-230. 
51. Djarv T, Metcalfe C, Avery KN, Lagergren P, Blazeby JM. Prognostic value of 
changes in health-related quality of life scores during curative treatment for 
esophagogastric cancer. J Clin Oncol. 2010;28(10):1666-1670. 
52. Djärv T, Lagergren P. Six-month postoperative quality of life predicts long-term 
survival after oesophageal cancer surgery. European Journal of Cancer. 
2011;47(4):530-535. 
53. Djarv T, Blazeby JM, Lagergren P. Predictors of postoperative quality of life after 
esophagectomy for cancer. J Clin Oncol. 2009;27(12):1963-1968. 
54. Schmidt CE, Bestmann B, Kuchler T, Schmid A, Kremer B. Quality of life associated 
with surgery for esophageal cancer: differences between collar and intrathoracic 
anastomoses. World J Surg. 2004;28(4):355-360. 
55. Backemar L, Wikman A, Djarv T, Johar A, Lagergren P. Co-morbidity after 
oesophageal cancer surgery and recovery of health-related quality of life. The British 
journal of surgery. 2016;103(12):1665-1675. 
56. Klevebro F, Kauppila JH, Markar S, Johar A, Lagergren P. Health‐related quality of 
life following total minimally invasive, hybrid minimally invasive or open 
oesophagectomy: a population‐based cohort study. Brit J Surg. 2021;108(6):702-
708. 
57. Anandavadivelan P, Wikman A, Johar A, Lagergren P. Impact of weight loss and 
eating difficulties on health-related quality of life up to 10 years after 
oesophagectomy for cancer. The British journal of surgery. 2018;105(4):410-418. 
58. Nonon JC. Introduction to Medical Psychology. New York: Free Press; 1982. 
59. Hellstadius Y, Lagergren J, Zylstra J, et al. A longitudinal assessment of 
psychological distress after oesophageal cancer surgery. Acta Oncol. 2017;56(5):746-
752. 
60. Dempster M, McCorry NK, Brennan E, Donnelly M, Murray L, Johnston BT. 
Psychological distress among survivors of esophageal cancer: the role of illness 
cognitions and coping. Dis Esophagus. 2012;25(3):222-227. 
61. Bouras G, Markar SR, Burns EM, et al. Linked Hospital and Primary Care Database 
Analysis of the Incidence and Impact of Psychiatric Morbidity Following 
Gastrointestinal Cancer Surgery in England. Ann Surg. 2016;264(1):93-99. 
62. Wikman A, Ljung R, Johar A, Hellstadius Y, Lagergren J, Lagergren P. Psychiatric 
morbidity and survival after surgery for esophageal cancer: a population-based cohort 
study. J Clin Oncol. 2015;33(5):448-454. 
63. Hellstadius Y, Lagergren P, Lagergren J, Johar A, Hultman CM, Wikman A. Aspects 
of emotional functioning following oesophageal cancer surgery in a population-based 
cohort study. Psycho-oncology. 2015;24(1):47-53. 
 
 51 
64. Linden W, Vodermaier A, Mackenzie R, Greig D. Anxiety and depression after 
cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 
2012;141(2-3):343-351. 
65. Carver CS, Scheier MF, Segerstrom SC. Optimism. Clinical psychology review. 
2010;30(7):879-889. 
66. Scheier MF, Carver CS, Bridges MW. Distinguishing optimism from neuroticism 
(and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life 
Orientation Test. J Pers Soc Psychol. 1994;67(6):1063-1078. 
67. Scheier MF, Carver CS. Optimism, coping, and health: assessment and implications 
of generalized outcome expectancies. Health psychology : official journal of the 
Division of Health Psychology, American Psychological Association. 1985;4(3):219-
247. 
68. Bredal IS, Ekeberg Ø. The Stability of Dispositional Optimism in Relation to 
Receiving or Not Receiving a Cancer Diagnosis. Psychology. 2016;07(06):806-814. 
69. Schou I, Ekeberg O, Sandvik L, Ruland CM. Stability in optimism-pessimism in 
relation to bad news: a study of women with breast cancer. J Pers Assess. 
2005;84(2):148-154. 
70. Mosing MA, Zietsch BP, Shekar SN, Wright MJ, Martin NG. Genetic and 
environmental influences on optimism and its relationship to mental and self-rated 
health: a study of aging twins. Behavior genetics. 2009;39(6):597-604. 
71. Plomin R, Scheier MF, Bergeman CS, Pedersen NL, Nesselroade JR, McClearn GE. 
Optimism, pessimism and mental health: A twin/adoption analysis. Personality and 
Individual Differences. 1992;13(8):921-930. 
72. Heinonen K, Räikkönen K, Keltikangas-Järvinen L. Dispositional optimism: 
development over 21 years from the perspectives of perceived temperament and 
mothering. Personality and Individual Differences. 2005;38(2):425-435. 
73. Heinonen K, Raikkonen K, Matthews KA, et al. Socioeconomic status in childhood 
and adulthood: associations with dispositional optimism and pessimism over a 21-
year follow-up. J Pers. 2006;74(4):1111-1126. 
74. Segerstrom SC. Optimism and Resources: Effects on Each Other and on Health over 
10 Years. Journal of research in personality. 2007;41(4). 
75. Malouff JM, Schutte NS. Can psychological interventions increase optimism? A 
meta-analysis. The Journal of Positive Psychology. 2016;12(6):594-604. 
76. Marshall GN, Wortman CB, Kusulas JW, Hervig LK, et a. Distinguishing optimism 
from pessimism: Relations to fundamental dimensions of mood and personality. J 
Pers Soc Psychol. 1992;62(6):1067-1074. 
77. Chang EC, D'Zurilla TJ, Maydeu-Olivares A. Assessing the dimensionality of 
optimism and pessimism using a multimeasure approach. Cognitive Therapy and 
Research. 1994;18(2):143-160. 
78. Glaesmer H, Rief W, Martin A, et al. Psychometric properties and population-based 




79. Herzberg PY, Glaesmer H, Hoyer J. Separating optimism and pessimism: a robust 
psychometric analysis of the revised Life Orientation Test (LOT-R). Psychol Assess. 
2006;18(4):433-438. 
80. Zenger M, Finck C, Zanon C, Jimenez W, Singer S, Hinz A. Evaluation of the Latin 
American version of the Life Orientation Test-Revised. Int J Clin Hlth Psyc. 
2013;13(3):243-252. 
81. Creed PA, Patton W, Bartrum D. Multidimensional Properties of the LOT-R: Effects 
of Optimism and Pessimism on Career and Well-Being Related Variables in 
Adolescents. Obes Surg. 2016;10(1):42-61. 
82. Robinson-Whelen S, Kim C, MacCallum RC, Kiecolt-Glaser JK. Distinguishing 
optimism from pessimism in older adults: is it more important to be optimistic or not 
to be pessimistic? J Pers Soc Psychol. 1997;73(6):1345-1353. 
83. Alessandri G, Vecchione M, Fagnani C, et al. Much More Than Model Fitting? 
Evidence for the Heritability of Method Effect Associated With Positively Worded 
Items of the Life Orientation Test Revised. Structural Equation Modeling: A 
Multidisciplinary Journal. 2010;17(4):642-653. 
84. Monzani D, Steca P, Greco A. Brief report: Assessing dispositional optimism in 
adolescence--factor structure and concurrent validity of the Life Orientation Test--
Revised. J Adolesc. 2014;37(2):97-101. 
85. Steca P, Monzani D, Pierobon A, Avvenuti G, Greco A, Giardini A. Measuring 
dispositional optimism in patients with chronic heart failure and their healthcare 
providers: the validity of the Life Orientation Test-Revised. Patient Prefer 
Adherence. 2017;11:1497-1503. 
86. Vautier S, Raufaste E, Cariou M. Dimensionality of the Revised Life Orientation Test 
and the status of filler items. International Journal of Psychology. 2003;38(6):390-
400. 
87. Vecchione M, Alessandri G, Caprara GV, Tisak J. Are Method Effects Permanent or 
Ephemeral in Nature? The Case of the Revised Life Orientation Test. Structural 
Equation Modeling: A Multidisciplinary Journal. 2014;21(1):117-130. 
88. Rauch WA, Schweizer K, Moosbrugger H. Method effects due to social desirability 
as a parsimonious explanation of the deviation from unidimensionality in LOT-R 
scores. Personality and Individual Differences. 2007;42(8):1597-1607. 
89. Pan TM, Mills SD, Fox RS, et al. The Psychometric Properties of English and 
Spanish Versions of the Life Orientation Test-Revised in Hispanic Americans. J 
Psychopathol Behav Assess. 2017;39(4):657-668. 
90. Carver CS, Scheier MF. Dispositional optimism. Trends Cogn Sci. 2014;18(6):293-
299. 
91. Carver CS, Gaines JG. Optimism, pessimism, and postpartum depression. Cognitive 
Therapy and Research. 1987;11(4):449-462. 
92. Shnek ZM, Irvine J, Stewart D, Abbey S. Psychological factors and depressive 
symptoms in ischemic heart disease. Health psychology : official journal of the 




93. Giltay EJ, Zitman FG, Kromhout D. Dispositional optimism and the risk of 
depressive symptoms during 15 years of follow-up: the Zutphen Elderly Study. J 
Affect Disord. 2006;91(1):45-52. 
94. Ai AL, Carretta H. Optimism/hope associated with low anxiety in patients with 
advanced heart disease controlling for standardized cardiac confounders. J Health 
Psychol. 2020;25(13-14):2520-2527. 
95. David D, Montgomery GH, Bovbjerg DH. Relations between coping responses and 
optimism-pessimism in predicting anticipatory psychological distress in surgical 
breast cancer patients. Pers Individ Dif. 2006;40(2):203-213. 
96. Zenger M, Brix C, Borowski J, Stolzenburg JU, Hinz A. The impact of optimism on 
anxiety, depression and quality of life in urogenital cancer patients. Psycho-oncology. 
2010;19(8):879-886. 
97. Horney DJ, Smith HE, McGurk M, et al. Associations between quality of life, coping 
styles, optimism, and anxiety and depression in pretreatment patients with head and 
neck cancer. Head Neck. 2011;33(1):65-71. 
98. Rajandram RK, Ho SM, Samman N, Chan N, McGrath C, Zwahlen RA. Interaction 
of hope and optimism with anxiety and depression in a specific group of cancer 
survivors: a preliminary study. BMC research notes. 2011;4:519. 
99. Allison PJ, Guichard C, Gilain L. A prospective investigation of dispositional 
optimism as a predictor of health-related quality of life in head and neck cancer 
patients. Qual Life Res. 2000;9(8):951-960. 
100. de Moor JS, de Moor CA, Basen-Engquist K, Kudelka A, Bevers MW, Cohen L. 
Optimism, distress, health-related quality of life, and change in cancer antigen 125 
among patients with ovarian cancer undergoing chemotherapy. Psychosom Med. 
2006;68(4):555-562. 
101. Colby DA, Shifren K. Optimism, mental health, and quality of life: a study among 
breast cancer patients. Psychology, health & medicine. 2013;18(1):10-20. 
102. Yoon H, Kim Y, Lim YO, Lee HJ, Choi K. Factors affecting quality of life of older 
adults with cancer in Korea. Geriatrics & gerontology international. 2015;15(8):983-
990. 
103. Kung S, Rummans TA, Colligan RC, et al. Association of optimism-pessimism with 
quality of life in patients with head and neck and thyroid cancers. Mayo Clinic 
proceedings. 2006;81(12):1545-1552. 
104. Finck C, Barradas S, Zenger M, Hinz A. Quality of life in breast cancer patients: 
Associations with optimism and social support. International journal of clinical and 
health psychology : IJCHP. 2018;18(1):27-34. 
105. Schou I, Ekeberg O, Sandvik L, Hjermstad MJ, Ruland CM. Multiple predictors of 
health-related quality of life in early stage breast cancer. Data from a year follow-up 
study compared with the general population. Qual Life Res. 2005;14(8):1813-1823. 
106. Rasmussen HN, Scheier MF, Greenhouse JB. Optimism and physical health: a meta-
analytic review. Annals of behavioral medicine : a publication of the Society of 
Behavioral Medicine. 2009;37(3):239-256. 
107. Scheier MF, Carver CS. Dispositional optimism and physical health: A long look 
back, a quick look forward. Am Psychol. 2018;73(9):1082-1094. 
 
54 
108. Lee LO, James P, Zevon ES, et al. Optimism is associated with exceptional longevity 
in 2 epidemiologic cohorts of men and women. Proc Natl Acad Sci U S A. 
2019;116(37):18357-18362. 
109. Whitfield JB, Zhu G, Landers JG, Martin NG. Pessimism is associated with greater 
all-cause and cardiovascular mortality, but optimism is not protective. Sci Rep. 
2020;10(1):12609. 
110. Anthony EG, Kritz-Silverstein D, Barrett-Connor E. Optimism and Mortality in Older 
Men and Women: The Rancho Bernardo Study. J Aging Res. 2016;2016:5185104. 
111. Engberg H, Jeune B, Andersen-Ranberg K, Martinussen T, Vaupel JW, Christensen 
K. Optimism and survival: does an optimistic outlook predict better survival at 
advanced ages? A twelve-year follow-up of Danish nonagenarians. Aging Clin Exp 
Res. 2013;25(5):517-525. 
112. Tindle HA, Chang YF, Kuller LH, et al. Optimism, cynical hostility, and incident 
coronary heart disease and mortality in the Women's Health Initiative. Circulation. 
2009;120(8):656-662. 
113. Giltay EJ, Kamphuis MH, Kalmijn S, Zitman FG, Kromhout D. Dispositional 
optimism and the risk of cardiovascular death: the Zutphen Elderly Study. Arch Intern 
Med. 2006;166(4):431-436. 
114. Giltay EJ, Geleijnse JM, Zitman FG, Hoekstra T, Schouten EG. Dispositional 
optimism and all-cause and cardiovascular mortality in a prospective cohort of elderly 
dutch men and women. Arch Gen Psychiatry. 2004;61(11):1126-1135. 
115. Rozanski A, Bavishi C, Kubzansky LD, Cohen R. Association of Optimism With 
Cardiovascular Events and All-Cause Mortality: A Systematic Review and Meta-
analysis. JAMA Netw Open. 2019;2(9):e1912200. 
116. Schulz R, Bookwala J, Knapp JE, Scheier M, Williamson GM. Pessimism, age, and 
cancer mortality. Psychol Aging. 1996;11(2):304-309. 
117. Allison PJ, Guichard C, Fung K, Gilain L. Dispositional optimism predicts survival 
status 1 year after diagnosis in head and neck cancer patients. J Clin Oncol. 
2003;21(3):543-548. 
118. Price MA, Butow PN, Bell ML, et al. Helplessness/hopelessness, minimization and 
optimism predict survival in women with invasive ovarian cancer: a role for targeted 
support during initial treatment decision-making? Support Care Cancer. 
2016;24(6):2627-2634. 
119. Schofield PE, Stockler MR, Zannino D, et al. Hope, optimism and survival in a 
randomised trial of chemotherapy for metastatic colorectal cancer. Support Care 
Cancer. 2016;24(1):401-408. 
120. Schofield P, Ball D, Smith JG, et al. Optimism and survival in lung carcinoma 
patients. Cancer. 2004;100(6):1276-1282. 
121. Schandl A, Johar A, Anandavadivelan P, Vikstrom K, Malberg K, Lagergren P. 
Patient-reported outcomes 1 year after oesophageal cancer surgery. Acta Oncol. 
2020;59(6):613-619. 
122. Ludvigsson JF, Almqvist C, Bonamy AK, et al. Registers of the Swedish total 
population and their use in medical research. Eur J Epidemiol. 2016;31(2):125-136. 
 
 55 
123. Ludvigsson JF, Svedberg P, Olén O, Bruze G, Neovius M. The longitudinal 
integrated database for health insurance and labour market studies (LISA) and its use 
in medical research. Eur J Epidemiol. 2019;34(4):423-437. 
124. Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the 
Swedish national inpatient register. BMC public health. 2011;11(1):450. 
125. Barlow L, Westergren K, Holmberg L, Talbäck M. The completeness of the Swedish 
Cancer Register – a sample survey for year 1998. Acta Oncol. 2009;48(1):27-33. 
126. Muhonen T, Torkelson EVA. Kortversioner av frågeformulär inom arbets- och 
hälsopsykologi—om att mäta coping och optimism. Nordisk Psykologi. 
2013;57(3):288-297. 
127. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta psychiatrica 
Scandinavica. 1983;67(6):361-370. 
128. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety 
and Depression Scale. An updated literature review. J Psychosom Res. 2002;52(2):69-
77. 
129. Hranov LG. Comorbid anxiety and depression: illumination of a controversy. Int J 
Psychiatry Clin Pract. 2007;11(3):171-189. 
130. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for 
Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in 
international clinical trials in oncology. Journal of the National Cancer Institute. 
1993;85(5):365-376. 
131. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. EORTC 
QLQ-C30 Scoring Manual. 3rd ed. Brussels, Belgium: European Organisation for 
Research and Treatment of Cancer; 2001. 
132. Giesinger JM, Kieffer JM, Fayers PM, et al. Replication and validation of higher 
order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. 
J Clin Epidemiol. 2016;69:79-88. 
133. Lagergren P, Fayers P, Conroy T, et al. Clinical and psychometric validation of a 
questionnaire module, the EORTC QLQ-OG25, to assess health-related quality of life 
in patients with cancer of the oesophagus, the oesophago-gastric junction and the 
stomach. European journal of cancer (Oxford, England : 1990). 2007;43(14):2066-
2073. 
134. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. 
Evidence-based guidelines for determination of sample size and interpretation of the 
European Organisation for the Research and Treatment of Cancer Quality of Life 
Questionnaire Core 30. J Clin Oncol. 2011;29(1):89-96. 
135. King MT. The interpretation of scores from the EORTC quality of life questionnaire 
QLQ-C30. Qual Life Res. 1996;5(6):555-567. 
136. Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evidence-based 
medicine. 2016;21(4):125-127. 
137. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed: Lippincott 
Williams & Wilkins; 2008. 




139. Bell ML, Fairclough DL. Practical and statistical issues in missing data for 
longitudinal patient-reported outcomes. Stat Methods Med Res. 2014;23(5):440-459. 
140. Wu L, Liu W, Yi GY, Huang Y. Analysis of Longitudinal and Survival Data: Joint 
Modeling, Inference Methods, and Issues. Journal of Probability and Statistics. 
2012;2012:640153. 
141. Hutcheon JA, Chiolero A, Hanley JA. Random measurement error and regression 
dilution bias. BMJ. 2010;340:c2289. 
142. Keogh RH, Strawbridge AD, White I. Correcting for Bias due to Misclassification 
when Error-prone Continuous Exposures Are Misclassified. Epidemiologic Methods. 
2012;1(1). 
143. Allison PD. Fixed Effects Regression Models. Thousand Oaks, California: SAGE 
Publications Inc; 2009. 
144. Kirkwood BR, Sterne JAC. Essential medical statistics. 2nd ed. Malden, Mass.: 
Blackwell Science; 2003. 
145. Thalen-Lindstrom AM, Glimelius BG, Johansson BB. Identification of Distress in 
Oncology Patients: A Comparison of the Hospital Anxiety and Depression Scale and 
a Thorough Clinical Assessment. Cancer nursing. 2016;39(2):E31-39. 
146. Swarm RA, Paice JA, Anghelescu DL, et al. Adult Cancer Pain, Version 3.2019, 
NCCN Clinical Practice Guidelines in Oncology. Journal of the National 
Comprehensive Cancer Network J Natl Compr Canc Netw. 2019;17(8):977-1007. 
147. Chetty S, Friedman AR, Taravosh-Lahn K, et al. Stress and glucocorticoids promote 
oligodendrogenesis in the adult hippocampus. Molecular psychiatry. 
2014;19(12):1275-1283. 
148. Cattaneo A, Riva MA. Stress-induced mechanisms in mental illness: A role for 
glucocorticoid signalling. The Journal of Steroid Biochemistry and Molecular 
Biology. 2016;160:169-174. 
149. Saphire-Bernstein S, Way BM, Kim HS, Sherman DK, Taylor SE. Oxytocin receptor 
gene (OXTR) is related to psychological resources. Proc Natl Acad Sci U S A. 
2011;108(37):15118-15122. 
150. Mosing MA, Medland SE, McRae A, Landers JG, Wright MJ, Martin NG. Genetic 
influences on life span and its relationship to personality: a 16-year follow-up study of 
a sample of aging twins. Psychosom Med. 2012;74(1):16-22. 
151. Lee LO, Aldwin CM, Kubzansky LD, Mroczek DK, Spiro A. The long arm of 
childhood experiences on longevity: Testing midlife vulnerability and resilience 
pathways. Psychol Aging. 2019;34(7):884-899. 
152. Nes LS, Segerstrom SC. Dispositional optimism and coping: a meta-analytic review. 
Pers Soc Psychol Rev. 2006;10(3):235-251. 
153. Buyukasik-Colak C, Gundogdu-Akturk E, Bozo O. Mediating role of coping in the 
dispositional optimism-posttraumatic growth relation in breast cancer patients. The 
Journal of psychology. 2012;146(5):471-483. 
154. Ramirez-Maestre C, Esteve R, Lopez-Martinez AE, Serrano-Ibanez ER, Ruiz-Parraga 
GT, Peters M. Goal Adjustment and Well-Being: The Role of Optimism in Patients 
with Chronic Pain. Annals of behavioral medicine : a publication of the Society of 
Behavioral Medicine. 2019;53(7):597-607. 
 
 57 
155. Willis K, Timmons L, Pruitt M, Schneider HL, Alessandri M, Ekas NV. The 
Relationship Between Optimism, Coping, and Depressive Symptoms in Hispanic 
Mothers and Fathers of Children with Autism Spectrum Disorder. Journal of autism 
and developmental disorders. 2016;46(7):2427-2440. 
156. Wrosch C, Scheier MF. Personality and quality of life: the importance of optimism 
and goal adjustment. Qual Life Res. 2003;12 Suppl 1(1):59-72. 
157. Trunzo JJ, Pinto BM. Social support as a mediator of optimism and distress in breast 
cancer survivors. J Consult Clin Psychol. 2003;71(4):805-811. 
158. Garner MJ, McGregor BA, Murphy KM, Koenig AL, Dolan ED, Albano D. 
Optimism and depression: a new look at social support as a mediator among women 
at risk for breast cancer. Psycho-oncology. 2015;24(12):1708-1713. 
159. Vollmann M, Antoniw K, Hartung FM, Renner B. Social Support as Mediator of the 
Stress Buffering Effect of Optimism: The Importance of Differentiating the 
Recipients’ and Providers’ Perspective. European Journal of Personality. 
2020;25(2):146-154. 
160. Deimling GT, Wagner LJ, Bowman KF, Sterns S, Kercher K, Kahana B. Coping 
among older-adult, long-term cancer survivors. Psycho-oncology. 2006;15(2):143-
159. 
161. van de Wiel M, Derijcke S, Galdermans D, et al. Coping Strategy Influences Quality 
of Life in Patients With Advanced Lung Cancer by Mediating Mood. Clinical Lung 
Cancer. 2021;22(2):e146-e152. 
162. Fasano J, Shao T, Huang H-h, Kessler AJ, Kolodka OP, Shapiro CL. Optimism and 
coping: do they influence health outcomes in women with breast cancer? A systemic 
review and meta-analysis. Breast Cancer Res Tr. 2020;183(3):495-501. 
163. Lam WWT, Yeo W, Suen J, et al. Goal adjustment influence on psychological well-
being following advanced breast cancer diagnosis. Psycho-oncology. 2016;25(1):58-
65. 
164. Zhu L, Ranchor AV, van der Lee M, Garssen B, Sanderman R, Schroevers MJ. The 
role of goal adjustment in symptoms of depression, anxiety and fatigue in cancer 
patients receiving psychosocial care: A longitudinal study. Psychology & Health. 
2015;30(3):268-283. 
165. Barlow MA, Wrosch C, McGrath JJ. Goal adjustment capacities and quality of life: A 
meta-analytic review. Journal of Personality. 2020;88(2):307-323. 
166. Strayhorn SM, Bergeron NQ, Strahan DC, et al. Understanding the relationship 
between positive and negative social support and the quality of life among African 
American breast cancer survivors. Supportive Care in Cancer. 2021;29(9):5219-5226. 
167. Hofman A, Zajdel N, Klekowski J, Chabowski M. Improving Social Support to 
Increase QoL in Lung Cancer Patients. CANCER MANAGEMENT AND RESEARCH. 
2021;13:2319-2327. 
168. Bou-Samra P, Scott P, Cheng H, et al. Social Support is Associated with Survival in 




169. Boehm JK, Chen Y, Koga H, Mathur MB, Vie LL, Kubzansky LD. Is Optimism 
Associated With Healthier Cardiovascular-Related Behavior? Meta-Analyses of 3 
Health Behaviors. Circulation research. 2018;122(8):1119-1134. 
170. Ikeda A, Schwartz J, Peters JL, et al. Pessimistic orientation in relation to telomere 
length in older men: the VA normative aging study. Psychoneuroendocrinology. 
2014;42:68-76. 
171. Roy B, Diez-Roux AV, Seeman T, Ranjit N, Shea S, Cushman M. Association of 
optimism and pessimism with inflammation and hemostasis in the Multi-Ethnic Study 
of Atherosclerosis (MESA). Psychosom Med. 2010;72(2):134-140. 
172. Boehm JK, Williams DR, Rimm EB, Ryff C, Kubzansky LD. Relation between 
optimism and lipids in midlife. Am J Cardiol. 2013;111(10):1425-1431. 
173. Ludvigsson JF. The first eight months of Sweden's COVID-19 strategy and the key 
actions and actors that were involved. Acta Paediatr. 2020;109(12):2459-2471. 
174. Wang Q, Berger NA, Xu R. Analyses of Risk, Racial Disparity, and Outcomes 
Among US Patients With Cancer and COVID-19 Infection. JAMA oncology. 
2021;7(2):220-227. 
175. Giannakoulis VG, Papoutsi E, Siempos, II. Effect of Cancer on Clinical Outcomes of 
Patients With COVID-19: A Meta-Analysis of Patient Data. JCO Glob Oncol. 
2020;6(6):799-808. 
176. Luo L, Fu M, Li Y, et al. The potential association between common comorbidities 
and severity and mortality of coronavirus disease 2019: A pooled analysis. Clin 
Cardiol. 2020;43(12):1478-1493. 
 
